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ABSTRACT 
 
Diabetes mellitus comprises a cohort of genetic and metabolic diseases which are 
characterized by the hallmark symptom of hyperglycemia. Diabetic subtypes are based on 
their pathogenetic origins: the most prevalent subtypes are the autoimmune-mediated 
type 1 diabetes mellitus (T1DM) and the metabolic disease of type 2 diabetes mellitus 
(T2DM). Genetic factors are major contributory aspects to diabetes development, 
particularly in T2DM where there is close to 80% concordance rates between 
monozygotic twins. However, the functional state of the pancreatic β cell is of paramount 
importance to the development of diabetes. Perturbations that lead to β cell dysfunction 
impair insulin production and secretion and precede diabetes onset.  
The endoplasmic reticulum (ER) is a subcellular organelle network of tubes and 
cisternae with multifaceted roles in cellular metabolism. Alterations to ER function such 
as those begotten by the accumulation of misfolded and unfolded ER client proteins upset 
the ER homeostatic balance, leading to a condition termed ER stress. Subsequent sensing 
of ER stress by three ER transmembrane proteins, initiates an adaptive reaction to 
alleviate ER stress: this is known as the unfolded protein response (UPR). Divergent 
cascades of the UPR attempt to mitigate ER stress and restore ER homeostasis: Failing 
that, the UPR initiates pro-apoptotic pathways. The demand of insulin production on the 
β cell necessitates the presence of a highly functional ER. However, the consequence of 
dependence on the ER for insulin synthesis and secretion portends disaster for the 
functional state of the β cell. Disturbances to the ER that elicit ER stress and UPR 
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activation causes β cell dysfunction and may lead to apoptosis. There are numerous well-
characterized models of ER stress-mediated diabetes, including genetic mutations in UPR 
transducers and insulin. Recently, polymorphisms in Wolfram syndrome 1 (WFS1), an 
ER transmembrane protein involved in the UPR, were suggested to contribute to T2DM 
risk. 
In this thesis, one of the highlighted WFS1 polymorphism, H611R, was examined 
to identify its contribution to β cell function and viability, and hence, diabetes risk. It was 
revealed that augmentation of WFS1 expression increased insulin secretion and cellular 
content. In addition, WFS1 protected β cells against ER stress-mediated dysfunction, 
with a more pronounced effect in the WFS1-R611 protective allele. Subsequent gene 
expression analysis identified netrin-1 as a WFS1-induced survival factor. 
As a contributory factor to diabetes progression, ER stress and UPR are potential 
drug and biomarker targets. In this dissertation, a novel UPR-regulating microRNA 
(miRNA) family was uncovered in ER stressed, WFS1-deficient islets. These miRNAs, 
the miR-29 family, are induced in WFS1-/- islets as a possible adaptive alteration to 
chronic ER stress conditions, and indirectly decreases the expression of UPR transducers, 
while directly targeting downstream ER stress-related pro-apoptotic factors. 
Collectively, this work extends the function of WFS1 as a protective factor in the 
pancreatic β cell through the induction of netrin-1 signaling. Additionally, it further 
strengthens the role of miRNA as regulatory members of the UPR which contribute to 
cell survival. 
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CHAPTER I: 
INTRODUCTION 
 
THE PANCREATIC BETA CELL 
The pancreas is a flattened, retroperitoneal, glandular organ consisting of loosely-
structured acinar (or exocrine) glands and duct system involved in digestive enzyme 
production and secretion into the duodenum. Interspersed among the acinar tissue and 
comprising 1-2% of the pancreatic volume reside the endocrine islets of Langerhans, first 
described by the German pathologist Paul Langerhans in 1869 1. The islets harbor a 
number of endocrine cell types which vary in quantity and intrainsular location: these 
include the glucagon-secreting  cells, insulin-secreting  cells, somatostatin-producing 
 cells, polypeptide-producing PP cells, and ghrelin-secreting  cells 2. The major 
secretory product of the pancreatic β cell, insulin, is the sole glucoregulatory molecule 
produced by the body and is indispensable for maintaining whole body energy production 
and metabolism. 
 
1.1. Overview of pancreatic beta cell function 
Pancreatic  cells, which comprise 65-80% of each islet, are committed to the 
production, storage and secretion of the unique blood glucose-reducing hormone, insulin. 
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To achieve on-demand insulin production and secretion, the pancreatic  cell is 
functionally equipped. Indeed, proinsulin mRNA constitutes approximately 30% of all 
mRNA expressed in the  cell and proinsulin biosynthesis is induced 25-fold to almost 
50% of total protein production following glucose stimulation 3, 4. During glucose 
challenge, it is suggested that the ER of the pancreatic  cell synthesizes approximately 1 
million molecules of insulin per minute 5. To enable efficient and abundant production of 
insulin, the pancreatic  cell has an extensive ER network consisting of thin ER cisternae, 
in addition to efficient packaging, intracellular transport, and secretory systems. 
 
1.2. Insulin Production and Secretion 
There are approximately one million islets in a healthy human pancreas, each of 
which is primed to respond to respond to fluctuations in blood glucose levels. At the 
cellular level, the response to glucose has been fully elucidated: initially, glucose enters 
passively into  cells through cell surface-bound glucose transporter 2 (GLUT2) 
molecules. Subsequently, the six-carbon carbohydrate fuel is phosphorylated by 
glucokinase to form glucose-6-phosphate (glucose-6-P), trapping the carbohydrate within 
the cell. This is the rate-limiting step for glucose-stimulated insulin release. Enzymatic 
degradation of glucose-6-P in the glycolytic pathway leads to an increase in ATP 
concentration, elevating the ATP: ADP ratio and stimulating the closure of ATP-sensitive 
K+ channels. Consequently, the rise in the intracellular potassium ion concentration of the 
β cell leads to depolarization of the β cell plasma membrane, which stimulates the 
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opening of membrane-bound voltage-gated Ca2+ channels. The subsequent influx of Ca2+ 
ions into the  cell dramatically increases the concentration of free cytoplasmic Ca2+ ions, 
which activates exocytosis of insulin secretory granules (Figure 1.1).  
Following glucose challenge, the first-phase of insulin is released in pulsatile 
manner from the β cell. The biosynthesis of nascent insulin molecules is also initiated by 
induction of transcription from the Insulin gene. Cytoplasmic insulin mRNA forms the 
templates to derive preproinsulin, which is co-translationally translocated into the ER 
lumen with coincident cleavage of the N-terminal ER-localizing signal peptide, to yield 
proinsulin. The concerted action of chaperones, foldases and isomerases in the ER lumen 
direct the precise folding and disulphide bond formation consistent with the characteristic 
proinsulin structure 6. Proinsulin is subsequently transported to the Golgi and packaged 
into secretory vesicles, where mature insulin is generated following the enzymatic 
cleavage by specific endopeptidases. Secretory vesicles may be made and secreted on-
demand or stored as mature readily-releasable pools, which are in close proximity to the 
plasma membrane. However, glucose stimulation releases young secretory vesicles 
preferentially during the initial phase, followed by the recruitment of older vesicles for 
secretion 7. 
Insulin secretion responds to increasing circulating levels of glucose, the major 
insulin secretagogue. However, amino acids, ketones, gastrointestinal peptides and 
neurotransmitters also influence insulin secretion. Clinically, a number of compounds are 
used to achieve insulin release to maintain blood normoglycemia. The aforementioned 
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ATP-sensitive K+ channels contain binding sites for oral hypoglycemic drugs, such as the 
sulfonylureas and meglitinides, which cause depolarization and insulin release. 
Neuroendocrine cells of the gastrointestinal trace release the incretins glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in response to 
dietary nutrients. Incretins stimulate the synthesis and release of insulin from β cells and 
promote β cell growth and survival 8, 9. Incretin-based therapies that stimulate insulin 
release include GLP-1 analogs and dipeptidyl peptidase-4 (DPP-4, the incretin 
inactivator) inhibitors. 
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Figure 1.1: Sequence of events leading to insulin secretion by the pancreatic β cell 
following glucose challenge. Glucose enters via the GLUT2 transporter and is quickly 
phosphorylated by glucokinase into glucose-6-phosphate. Metabolism of glucose results 
in an increase in the ATP: ADP ratio. This alteration inactivates the ATP-sensitive 
potassium channel, leading to accumulation of intracellular potassium ions, which 
triggers membrane depolarization. Subsequently, the voltage-gated calcium channel 
opens, allowing calcium ions to flow into the β cell. The resulting rise in calcium 
concentration leads to the exocytosis of insulin from their storage vesicles. 
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1.3. Peripheral insulin action and glucose regulation 
Following secretion, insulin travels via the hepatic portal vein to the liver, where 
the majority is degraded. The remaining circulating insulin is dispersed throughout the 
body by the bloodstream where it binds to cell surface-bound insulin receptors on muscle 
and adipose tissue. Insulin binding to the insulin receptor, a receptor tyrosine kinase 
family member, leads to the trans-autophosphorylation of intracellular tyrosine residues 
10. Activation of the insulin receptor initiates an intracellular signaling cascade which 
involves the recruitment and phosphorylation of a number of adaptor proteins, including 
the insulin receptor substrate (ISR) proteins 11-13. Downstream of the IRS proteins, two 
major kinase families are activated: these are the phosphatidylinositol-3 kinase (PI3 
kinase) family, which is involved in the metabolic effects of insulin, and the mitogen-
activated protein kinase (MAPK) pathway, which mediates the mitogenic effects of 
insulin 14.  
The goal of insulin release is to restore blood normoglycemia. To achieve this 
insulin promotes glucose uptake into muscle and adipose tissues by stimulating the 
translocation of GLUT4 glucose transporters to the cell surface 12-13. In addition, insulin 
signals the storage of glucose and other fuels in the liver and adipose tissue by activating 
glycogen synthesis, protein synthesis, and lipogenesis 12, 13, 15-18. To maintain 
normoglycemic levels, insulin also reduces glucose output from the liver by decreasing 
the expression of gluconeogenic enzymes 12. 
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DIABETES MELLITUS 
Diabetes mellitus (DM) has been recognized for over two thousand years and was 
originally described as a disease of the kidneys and urinary tract due to the presenting 
symptom of excessive urinary output. The term “diabetes mellitus” derives from the 
Greek diabētēs, meaning siphon, and the Latin mellitus, honey-sweet, and together they 
relate to glycosuria, the excretion of glucose into the urine as the body loses its ability to 
maintain normal blood glucose levels. It was not until the late nineteenth century that the 
pancreas was connected to diabetes when the German physician-researchers Oskar 
Minkowski and Johann von Mering observed that pancreatectomized dogs developed 
diabetes, leading to death 19. Further research on the pancreas lead to the discovery of 
insulin by the Canadian surgeon, Frederick Banting, and his medical student assistant, 
Charles Best, in 1921 19. 
DM is one of the most prevalent and chronic diseases in the world with significant 
impact on economic and healthcare resources. As of 2011, the American Diabetes 
Association (ADA) report approximately 25.8 million people in the United States (8.3% 
of the population) with a confirmed diagnosis of DM. In addition, individuals considered 
pre-diabetic exceeds 80 million, highlighting the vast enormity of diabetes as a major 
disease 20. On a global scale, the World Health Organization (WHO) estimates that DM 
affects 220 million people worldwide, with a forecast of an explosion of DM incidence 
worldwide to 366 million people by 2030 21. 
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1.4. Classification of diabetes subtypes 
Diabetes mellitus is not a single disease, but encompasses a collection of 
metabolic and genetic diseases of different etiologies, each of which is characterized by 
the hyperglycemic state, as outlined in Figure 1.2. The plasma glycemic state is classified 
into three categories based on fasting blood glucose (FBG): (1) FBG < 5.6 mmol/L 
(100mg/dL) is normoglycemic; (2) FBG = 5.6-6.9 mmol/L (100-125mg/dL) is defined as 
impaired fasting glucose (IFG), or pre-diabetic; and (3) FBG ≥ 7.0 mmol/l (126mg/dL) 
indicates hyperglycemia and warrants the diagnosis of DM. Currently, the criteria to 
confirm the diagnosis of DM include: (A) FBG readings above 7mmol/L (126mg/dL), 
(B) 2-hour blood glucose readings greater than 11.1mmol/L (200mg/dL) following oral 
glucose tolerance test (OGTT), or (C) random blood glucose test above 11.1mol/L 
(200mg/dL) with accompanying diabetic symptoms of increased urinary frequency, 
increased thirst or unexplained weight loss.  
Classification of DM is based on the pathological process that precedes the onset 
of hyperglycemia. The two major forms of DM include type 1 (T1DM) and type 2 
(T2DM). On one end of the spectrum of diabetes lies T1DM, with near-complete insulin 
deficiency. T1DM is further subdivided into the immune-mediated type 1A and 
idiopathic type 1B forms. Recently, a number of novel preproinsulin gene mutations 
associated with monogenic DM have been discovered and termed „mutant Ins-gene-
induced diabetes of youth‟ (MIDY) that also causes hyperglycemic states through almost 
complete insulin deficiency 22-24. 
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On the other extreme of the DM spectrum is T2DM, a heterogenous group of 
disorders characterized by variable degrees of insulin resistance, impaired insulin 
secretion, and increased glucose production. DM may also manifest as a result of 
particular genetic or metabolic defects that affect insulin secretion or action. One subtype 
of DM consists of the autosomally dominant maturity onset diabetes of the young 
(MODY) forms, which encompass genetic defects in hepatocyte nuclear transcription 
factor (HNF) 4α (MODY1), glucokinase (MODY2), HNF-1α (MODY3), insulin 
promoter factor-1 (IPF-1) (MODY4), HNF-1β (MODY5), and neuroD1 (MODY6) 25.  
Hyperglycemia can manifest as a result of other genetic syndromes that are 
associated with DM including Klinefelter‟s, Turner‟s, and Prader-Willi syndromes. 
Genetic mutations in the Wfs1 or CISD2 genes lead to the development of Wolfram 
syndrome, a complex disease also known by the acronym DIDMOAD due to the clinical 
presentation of diabetes insipidus, diabetes mellitus, optical atrophy and deafness. 
Wolfram syndrome is discussed in more detail later in this introductory chapter. 
Hyperglycemic states due to glucose intolerance may also arise during pregnancy 
(gestational diabetes). Finally, DM may also arise following exposure to particular drug 
classes, including glucocorticoids, antipsychotics, and HIV protease inhibitors. 
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Figure 1.2:  The spectrum of DM diseases. DM with absolute insulin deficiency 
includes types 1A and 1B DM, mutant Ins-gene diabetes of the youth (MIDY), and 
Wolfram syndrome. Latent autoimmune diabetes of adults (LADA; type 1.5 DM) is a 
slowly-progressive form of T1DM. The maturity-onset diabetes of the young (MODY) 
forms of DM comprises a collection of hereditary forms of DM that affect insulin 
secretion or action. T2DM is a heterogenous group of disorders with relative insulin 
deficiency. 
 
 
11 
 
ENDOPLASMIC RETICULUM STRESS 
Within most cells, there exist many distinct organelle compartments which differ 
by their structure, location, quantity and specific metabolic tasks. Cellular organelles, 
which include the nucleus, mitochondria, endoplasmic reticulum and Golgi network, 
lysosomes, centrioles, cytoskeleton, and vacuoles, work cooperatively to maintain 
cellular function, growth, signaling, and viability. The endoplasmic reticulum (ER) is a 
specialized cellular organelle with a distinct structural network of interconnected tubules, 
vesicles and cisternae. Functionally, the ER is the primary site for the synthesis, folding 
and modification of transmembrane and secreted proteins 26-28. In addition, the ER may 
be involved in lipid and steroid biosynthesis and is a major intracellular storage depot of 
calcium ions 29-31. The ER also contains multiple signaling molecules involved in 
intracellular signaling pathways. For the pancreatic β cell, the ER is extremely important 
to maintain efficient insulin production and secretion. 
In regards to protein synthesis, the ER contains numerous chaperones, foldases, 
oxidoreductases, and isomerases to achieve efficient folding of proteins. In addition, the 
ER compartment contains a reliable quality control system which guarantees homeostasis 
of the ER lumen. The state of ER homeostasis, or equilibrium, is defined as the unique 
dynamic balance between the functional demand on the ER and the capacity of the ER to 
respond. Pertaining to protein production, ER homeostasis would encompass the folding 
capacity of the ER following increased protein translational influx into the ER. The 
extensive ER network is extremely sensitive to alterations in homeostasis, which may 
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result from the accumulation of unfolded or misfolded proteins in the ER lumen, changes 
to the calcium flux across the ER membrane, or alteration to the redox potential of the ER 
lumen 32, 33. ER homeostasis can also be modified by signals emanating from the 
extracellular milieu: alterations in nutrient content such as amino acid deprivation, 
elevation of fatty acid or glucose concentration also perturb ER homeostasis 30-33. In 
addition, several drugs and chemical compounds have the ability to upset the homeostatic 
balance of the ER. Experimentally, the equilibrium of the ER can be offset in cell lines or 
animal models using chemical agents: these include tunicamycin, an inhibitor of N-linked 
glycoslation, and thapsigargin, an inhibitor of the sarco-endoplasmic reticulum Ca2+ 
ATP-ase (SERCA). Nevertheless, regardless of the inciting factor, the condition in which 
ER homeostasis is perturbed is entitled “ER stress”.  
 
1.5. Unfolded Protein Response 
Once ER homeostasis has been perturbed and ER stress has been induced, the ER 
initiates an adaptive cellular signaling cascade that attempts to alleviate ER stress and 
restore ER homeostasis: this is known as the unfolded protein response (UPR) 30, 34. 
Initially, the UPR was described in the budding yeast Saccharomyces cervisiae, where 
the ER transmembrane protein kinase Ire1p senses ER stress and activates the 
transcriptional expression of genes involved in protein folding and glycosylation and 
membrane biogenesis 34-36. In higher-order animals, the basic adaptive UPR mechanism 
is phylogenetically preserved although the complexity is increased to encompass protein 
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translational control and activation of apoptotic pathways 37-39. Thus, commencement of 
the UPR instigates an adaptive signaling response that attempts to restore ER homeostasis 
through four distinct mechanisms: the UPR increases the expression of protein-folding 
and modifying genes to facilitate protein folding and egress from the ER, attenuates 
protein translation in order to limit protein influx into the ER, activates the ER-associated 
proteasomal degradation (ERAD) to remove ER stress-inducing unfolded or misfolded 
proteins, and, in the event that ER homeostasis is not restored, initiates ER stress-
mediated apoptotic pathways. 
Perception of ER stress is achieved through the presence and response of three 
specific ER transmembrane UPR master regulators: these are activating transcription 
factor 6 (ATF6), inositol-requiring enzyme 1(IRE1), and double-stranded RNA-activated 
kinase (PKR)-like ER kinase (PERK) (Figure 1.3). An ER-resident chaperone, 
immunoglobulin heavy chain-binding protein (BiP, or glucose-regulated protein 78, 
GRP78) binds to the ER luminal domains of each transducer, maintaining their inactive 
state. Upon ER stress induction, BiP is sequestered away by the increasing volume of 
unfolded or misfolded proteins in the ER, leaving the UPR transducers amenable to 
activation. Subsequently, the transducers alter the activation status of distinct downstream 
protein effectors and modulate gene expression in an ER-to-nucleus signaling cascade 
termed the UPR. The initial response of the UPR is adaptive and aims to enhance the ER 
folding capacity by increasing the expression of ER chaperones and modifying enzymes. 
In addition, the protein load on the ER is decreased by a dual mechanism: decreasing 
protein influx into the ER by translational repression and mRNA degradation, and 
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increasing the efflux of accrued proteins via enhancing ER-associated degradation 
(ERAD) and autophagy 40-42. To maintain cellular homeostasis and obviate 
hyperactivation of UPR signaling, the UPR has an integrated feedback control system 
that can dampen the activation status of the UPR transducers and their downstream 
effectors. Finally, the UPR also has an inherent ability to promote cell survival factors or 
death effectors based on the nature, severity, and duration of the inciting ER stress 
inducer. 
 
1.5.1. ATF6 
ATF6 is a single-pass type II ER transmembrane protein with the cytoplasmic 
NH2-terminal domain encoding a transcription factor of the basic-leucine zipper (b-ZIP) 
family. The ER luminal domain of ATF6 is bound by the central UPR regulator, BiP 37, 
43. Following ER stress, BiP titrates away from ATF6, revealing a Golgi localization 
signal, permitting the relocation of the 90kDa ATF6 protein from the ER to the Golgi. 
There, ATF6 undergoes regulated intramembraneous proteolysis by the sequential 
enzymatic cleavages by site-1 protease (S1P) and site-2 protease (S2P), releasing a 
50kDa NH2-terminal proteolytic fragment, which enters the nucleus 
37, 44, 45. ATF6 binds 
to the cis-acting ER stress-response element (ERSE) in the promoter region of target 
genes such the ER chaperones BiP, glucose-regulated protein 94 (GRP94), protein 
disulfide isomerase (PDI), calreticulin, and ER protein 72 (ERp72) 37, 46. The resulting 
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increase in ER chaperone content enhances protein folding in the ER in an attempt to 
assuage ER stress due to accretion of unfolded proteins (Figure 1.3). 
 
1.5.2. IRE1 
IRE1 is a single-pass type I ER transmembrane protein that comprises serine-
threonine kinase and endoribonuclease moieties in the cytoplasmic COOH-terminal 
domain and an ER stress-sensing region in the ER luminal NH2-terminal domain and is 
highly conserved from yeast to humans 37, 47, 48. There are two IRE1 isoforms: the IRE1α 
isoform is expressed in all cells whereas the IRE1β isoform is restricted to the 
gastrointestinal tract 49, 50. Pursuant to ER stress induction, BiP dissociates from the IRE1 
luminal domain, allowing the dimerization of IRE1 molecules with subsequent trans-
autophosphorylation, which triggers the activation of the cytoplasmic endoribonuclease 
domain 51, 52. Active, phosphorylated IRE1 (P-IRE1) entraps the mRNA of the 
transcription factor X-box binding protein-1 (XBP-1) and endoribonucleolytically splices 
out a 26 nucleotide intron, generating spliced XBP1 mRNA (sXBP1) 53-55. IRE1 releases 
sXBP1 mRNA, which encodes a b-ZIP transcription factor that translocates to the 
nucleus and binds to the ER stress response-element (ERSE; CCAAT-N9-CCACG), 
ERSE-II (ATTGG-N-CCACG) or UPR-element (UPRE; TGACGTGG) in the promoter 
of various genes, including those involved in protein maturation, folding, and ER export 
56. Other target genes of sXBP1 consist of those genes that encode proteins involved in 
ERAD, such as ER degradation-enhancing α-mannosidase-like protein (EDEM) 57, 58. 
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Thus, the coordinated effort of IRE1 activation and XBP1 splicing function to increase 
the folding capacity of the ER while simultaneously decreasing the protein load on the 
ER by enhancing protein degradation. 
 
1.5.3. PERK 
The remaining UPR transducer is PERK which, like IRE1, is a single-pass type I 
ER transmembrane protein with its NH2-terminal domain acting as an ER stress sensor in 
the ER lumen 38. PERK activation proceeds in a manner similar to that of IRE1: BiP 
dissociation permits the dimerization of PERK molecules, followed by trans-
autophosphorylation to yield phosphorylated PERK (P-PERK) 31, 59, 60. The kinase 
domain of P-PERK directly phosphorylates the serine residue at position 51 on the α 
subunit of eukaryotic initiation factor 2 (eIF2α) 31, 45, 61, 62. P-eIF2α inhibits the GDP-GTP 
exchange by eIF2B, thus reducing the formation of the active translational initiation 
ternary complex which consequently drastically reduces protein translation. Thus, the 
activation of PERK leads to protein translation attenuation decreases the workload on the 
ER, permitting adaptive restoration of ER homeostasis. 
In contradiction to the general attenuation of protein translation, there occurs 
selective and more efficient translation of specific UPR target genes, including ATF4 45, 
63, 64. ATF4 functions as a bZIP transcription factor to induce the expression of the genes 
involved in amino acid transport, glutathione biosynthesis and reduction of oxidative 
stress. In addition, ATF4 induces the expression of the specific UPR target genes growth 
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arrest and DNA damage gene 34 (GADD34) and C/EBP-homologous protein (CHOP) 65. 
As part of the integrated feedback control system of the UPR, GADD34 interacts with 
protein phosphatase 1c (PP1c) and functions to remove the phosphate moiety from eIF2 
to allow recovery of protein translation and restore protein synthesis 37, 66, 67. Prolonged 
ER stress conditions extends the presence of ATF4, leading to the induction of CHOP 
expression, which is involved in ER stress-mediated apoptotic signaling. Overall, PERK 
activation permits temporary recovery from ER stress and activation of apoptosis if ER 
homeostasis is not achieved.  
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Figure 1.3: The unfolded protein response (UPR). In response to ER stress, the three 
arms of the UPR are activated: (1) PERK signaling leads to eIF2α phosphorylation and 
translational attenuation with paradoxical increased ATF4 transcription, which leads to 
induction of specific genes; (2) ATF6 is cleaved in the Golgi releasing a transcription 
factor that increases the expression of ER chaperones, CHOP, and XBP-1; (3) signaling 
through IRE1 leads to splicing of XBP-1 mRNA, leading to XBP-1-mediated 
upregulation of ER chaperones, ERAD proteins and p58IPK. 
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1.6. ER stress-mediated apoptosis 
Activation of the UPR by ER stress is an attempt to restore ER homeostasis and 
maintain cell viability 51, 68. However, persistent, unresolved ER stress forces the UPR to 
initiate apoptosis-inducing signaling 5, 69. The UPR has two fundamental apoptotic 
signaling mechanisms: IRE1-JNK signaling and induction of CHOP expression. The 
former signaling pathway involves the chronic activation of IRE1, which recruits the 
adaptor protein TNF receptor-associated factor 2 (TRAF2). The IRE1-TRAF2 complex 
enlists the apoptosis signal-regulating kinase 1 (ASK1), leading to the phosphorylation of 
c-Jun N-terminal kinase (JNK) 70. JNK influences apoptotic pathways by phosphorylation 
of B-cell lymphoma 2 (Bcl2) at the ER membrane suppressing its anti-apoptotic activity. 
JNK also phosphorylates Bcl-2 homology domain 3 (BH3)-only Bcl2 members, such as 
Bim, enhancing their pro-apoptotic role. The latter apoptotic signaling mechanism 
involves the increase in CHOP expression via the PERK-ATF4 and ATF6 arms of the 
UPR 64, 71. CHOP represses the promoter of the Bcl-2 gene, decreasing the level of the 
anti-apoptotic Bcl-2 protein, allowing unrestricted activity of the pro-apoptotic BH3-only 
proteins 72, 73. 
 
1.7. Physiological ER stress signaling 
The ability of the ER to perceive stress and activate a specific response to restore 
homeostasis indicates that this response is an intrinsic physiological event. In the 
pancreatic  cell, the overwhelming increase in insulin production following glucose 
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challenge imparts transient stress on the ER and necessitates UPR activation to maintain 
ER integrity 30, 69, 73. Physiological ER stress signaling has also been shown in the 
differentiation of B lymphocytes into antibody-secreting plasma cells 37, 74, 75. In myoblast 
differentiation, elements of the UPR were also activated 76. ER stress signaling has also 
been demonstrated in liver cells, osteoblasts and the renal tubular epithelium 77. In the 
differentiation of T helper cells and during T cell activation, activation of the ER stress 
and UPR were also noted 78, 79. Thus, UPR activation in response to ER stress is prevalent 
in a wide range of physiological roles and is involved in diverse developmental and 
metabolic processes.  
 
1.8. Pathological ER stress signaling 
Since ER stress and activation of the UPR can lead to the induction of apoptosis, 
upsetting the ER homeostatic balance, such as that brought about by an increase in 
protein misfolding or a decrease in the ER folding capacity, has the potential to lead to 
cellular dysfunction and disease. In numerous neurodegenerative disorders in which the 
formation of protein aggregates is a prominent feature, ER stress and UPR activation 
have been demonstrated to be integral to pathogenesis. These diseases include 
Parkinson‟s disease (PD), Alzheimer‟s disease (AD), retinitis pigmentosa (RP), 
amyotrophic lateral sclerosis (ALS), and Huntington disease (HD) 80-84. The UPR also 
becomes activated during viral infections as a means to control the replication of viruses 
intracellularly. PERK signaling attenuates viral protein synthesis 85. However, some 
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viruses including herpes simplex virus type I (HSV-I) have evolved to counteract this 
regulatory mechanism 86. In the field of cancer, hypoxia-induced UPR is strongly linked 
to tumor growth 87, 88. CHOP and XBP-1 signaling has been observed to be augmented in 
carcinogenesis and implicated with tumor growth 89, 90. The physiological role of UPR 
activation in plasma cell differentiation is extended in multiple myeloma where IRE1 and 
XBP-1 signaling is significantly increased 91. In the pathogenesis of atherosclerosis, 
oxidized lipids and homocysteine induce ER stress in vascular cells, while cholesterol in 
macrophages similarly stimulates the UPR 92, 93. 
 
ER STRESS-MEDIATED DIABETES 
Pancreatic β cells are particularly sensitive to alterations in ER homeostasis such 
that ER stress signaling and UPR activation have been strongly associated with diabetes 
pathogenesis. There are several physiological, environmental, and genetic conditions that 
alter the ER homeostasis of pancreatic β cells. Alterations in blood glucose or fatty acid 
levels due to diet or genetic disease impart physiological stress on β cells that are 
transduced into ER stress with subsequent activation of the UPR 94, 95. In addition, 
mutations in ER stress transducer or effector genes similarly cause ER stress and UPR 
activation, leading to β cell dysfunction or apoptosis.  
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1.9. Genetic forms of ER stress-mediated diabetes 
ER homeostasis is essential for the β cell‟s role in insulin production and genetic 
mutations that cause ER stress may engender β cell dysfunction. Mutations in the genes 
encoding ER-related proteins have the potential to perturb ER homeostasis. ER stress-
mediated pancreatic  cell death underlies the pathogenesis of a number of specific 
genetic diseases including Wolcott-Rallison syndrome, permanent neonatal diabetes 
(PND), and Wolfram syndrome (Figure 1.4).  
Mutations in the EIF2AK3 gene, which encodes the ER stress transducer PERK, 
leads to a condition known as Wolcott-Rallison syndrome. In this disease, decreased 
PERK kinase activity would diminish total eIF2  phosphorylation, preventing the 
attenuation of protein translation. Consequently, persistent proinsulin translation and 
protein influx into the ER would culminate in ER stress-mediated pancreatic  cell 
apoptosis. In PERK-/- mice, diabetes develops in the immediate neonatal period with 
associated elevations in IRE1 phosphorylation in the pancreatic islets, suggestive of ER 
stress 96, 97. However, meticulous examination of PERK-/- mice revealed defects in fetal 
pancreatic  cell development, decreasing the overall  cell mass in addition to 
dysfunctional  cells 97. Therefore, not only is a functional UPR signaling network 
necessary for maintaining pancreatic  cell function, but it is also a requirement for 
successful in utero pancreatic  cell generation. 
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Genetic mutations in the gene encoding eIF2α, a downstream signaling partner of 
the PERK pathway also has significant diabetogenic effects. Mutations at the serine-51 
phosphorylation site of eIF2 in the transgenic Eif2si+/tm1Rjk mouse lead to obesity, 
pancreatic  cell dysfunction, and diabetes 98. Mice homozygous for this mutation (Eif2si 
tm1Rjk/tm1Rjk) succumb to hypoglycemia during the neonatal period, with severe pancreatic 
 cell defects noted 99. Knockout of the PERK inhibitor, P58IPK, in a mouse model, also 
leads to a gradual development of diabetes due to increased apoptosis of pancreatic 
 cells, further highlighting the involvement of ER stress pathways and the PERK arm of 
UPR signaling in pancreatic  cell death and diabetogenesis 100. 
Permanent neonatal diabetes (PND) can manifest as a result of mutation in the 
transcription factors insulin promoter factor-1 (IPF-1) and forkhead box-P3 (FOXP3) in 
addition to the insulin secretory components glucokinase (GCK) and the pancreatic  cell 
ATP-sensitive K+ channel 101. However, ER stress-mediated pancreatic  cell death 
leading to PND may also arise through mutations in the preproinsulin (INS) gene 22, 23. 
The Akita mouse model of diabetes harbors a mutation in the Ins2 gene, leading to the 
substitution of cysteine for tyrosine at amino acid 96. This mutation prevents the 
formation of a critical disulphide bond, and leads to proinsulin misfolding, instigating ER 
stress and activation of the UPR and ultimately, pancreatic  cell death 98. Similarly, the 
Cys95Ser mutation in the Ins2 gene in the Munich mouse disrupts proinsulin folding, 
causing ER stress and UPR activation, and leads to severe  cell loss and development of 
diabetes 103. In humans, preproinsulin gene mutations associated with monogenic diabetes 
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have been termed „mutant INS-gene-induced diabetes of youth‟ (MIDY) 22-24. Expression 
of MIDY mutations in MIN6 insulinoma cells leads to induction of ER stress 104. Thus, 
the impact of INS gene mutations coupled with the burden of insulin production on the 
 cell combines to generate ER stress, leading to UPR activation,  cell dysfunction and 
contributes to diabetes. 
 
1.10. Acquired forms of ER stress-mediated diabetes 
In contrast to the genetic mutations that elicit primary ER dysfunction and 
contribute to early-onset diseases, including diabetes mellitus, secondary ER dysfunction 
arises as a result of other underlying conditions. This acquired form of ER dysfunction is 
involved in the progression of age-related diseases, such as diabetes mellitus and 
neurodegeneration. 
The concentration of blood glucose fluctuates continually as a result of ingestion 
of nutrients, metabolic activity and release of gluconeogenic hormones. The pancreatic 
 cell responds to high glucose levels by synthesizing and secreting insulin. Transient or 
chronic hyperglycemic conditions induce phosphorylation of IRE1 in  cells 8. Sustained 
hyperglycemia, however, leads to chronic hyperactivation of IRE1, precipitating the 
formation of oligomers of P-IRE on the ER membrane. Oligomeric P-IRE1 molecules 
induce conformational alterations to the endoribonuclease domains such that alternative 
ER-localized mRNA, including insulin mRNA, are recognized and degraded 8, 105, 106. 
Prolonged IRE1 activation also leads to TRAF-mediated JNK activation and apoptosis 70, 
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83. Thus, during periods of prolonged hyperglycemic (glucotoxic) conditions, 
IRE1 hyperactivation is promoted and results in insulin degradation and UPR-mediated 
 cell apoptosis (Figure 1.4) 
Type 2 DM has long been associated with increased body mass index (BMI) and 
obesity. Circulating free fatty acids (FFAs), especially the commonly-found saturated 
fatty acid palmitate (C16:0), results in the activation of UPR signaling in pancreatic 
 cells as demonstrated by PERK and eIF2 phosphorylation and the induction of ATF4 
and CHOP expression 107, 108. Palmitate also leads to IRE1 and ATF6 activation and 
increases the expression of numerous ER chaperones 107, 109. There has been a dramatic 
increase in obesity in the United States over the past few decades. With increased 
adiposity and subsequent metabolic dysregulation, the elevation in circulating free fatty 
acids has the potential to have lipotoxic effects on  cells, leading to diabetes 
progression. 
Other acquired forms of ER stress in the  cell include islet amyloid polypeptide 
(IAPP), reactive oxygen species (ROS), and inflammatory cytokines (Figure 1.4). 
Pancreatic  cells secrete other molecules in addition to insulin, such as the 37kDa islet 
amyloid polypeptide (IAPP). Islet amyloid is commonly found in the islets of T2DM 
patients at autopsy and has been reported to contribute to  cell dysfunction 110. IAPP is 
highly amyloidogenic and spontaneously forms ER membrane-destroying amyloid 
sheets, leading to ER stress 111-113. With the increased demand for insulin biosynthesis, 
there is simultaneous increased activity of oxidoreductase enzymes to form disulfide 
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bonds in insulin. Increased oxidative reactions in the ER generate toxic reactive oxygen 
species (ROS), which causes calcium leak from the ER, triggering activation of the UPR 
94. Inflammation is a predominant feature in both T1DM and T2DM. Inflammatory 
cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ) have been reported to induce 
nitric oxide (NO) signaling, which decreases sarco-endoplasmic reticulum Ca2+ ATPase 
2b (SERCA2b) pump activity, leading to the depletion of ER Ca2+ stores and inducing 
ER stress in β cells 94. Thus, inflammatory signals may lead to ER stress-mediated 
pancreatic β cell dysfunction or apoptosis, contributing to diabetogenesis.  
It is apparent that the ER is a fundamental organelle within the cell. Primary or 
secondary ER dysfunction has the potential to contribute to various forms of disease, 
including diabetes and neurodegeneration. Therefore, it is paramount to understand the 
signals emanating from ER stressed cells and identify an approach to resolve ER stress in 
order to dissipate ER dysfunction, maintain cell survival and prevent the progression to 
disease. 
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Figure 1.4:  Physiological and pathological ER stress and UPR activation in the 
pancreatic β cell. ER stress and UPR activation arise from diverse environmental and 
genetic conditions that perturb the ER homeostatic balance in the pancreatic β cell. 
Hyperglycemia can induce both physiological or pathological ER stress; circulating free 
fatty acids (FFAs) leads to ER stress; genetic conditions, including Insulin gene 
mutations, Wolfram syndrome, and Wolcott-Rallison syndrome, lead to diabetes mellitus; 
islet amyloid polypeptide (IAPP) fibrils cause ER stress in the β cell; reactive oxygen 
species (ROS) perturb ER homeostasis leading to ER stress; and inflammation, cause ER 
stress and UPR activation. 
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WOLFRAM SYNDROME 
Wolfram syndrome is a rare autosomal recessive neurodegenerative disorder with 
a prevalence of 1/100,000-700,000, characterized by early-onset, insulin-dependent DM 
and progressive optical atrophy (OA) in the first decade of life. The association of DM 
and optical atrophy was first described by the German ophthalmologist, Albrecht von 
Gräfe in 1858 114. Eighty year later, Wolfram and Wagener characterized for patients 
with a syndrome consisting of DM and optical atrophy, leading to the name Wolfram 
syndrome 115, 116. While juvenile-onset DM and OA are required for the diagnosis, many 
Wolfram syndrome patients also develop a number of associated symptoms including 
central diabetes insipidus, sensorineural hearing loss, peripheral neuropathy, urinary tract 
atony, ataxia, and diverse psychiatric illnesses including dementia, severe depression, and 
psychosis 117. For this reason, the acronym DIDMOAD (diabetes insipidus, diabetes 
mellitus, optical atrophy, and deafness) has also been attributed to the disease. Barrett and 
Bundey (1997) delineated the chronological appearance of clinical symptoms of Wolfram 
syndrome, as reproduced in Figure 1.5. However, more recent neuroradiological imaging 
studies and thorough neurological examinations have found cerebellar atrophy and ataxia, 
respectively, as early as the beginning of the second decade of life in Wolfram patients. 
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Figure 1.5:  Chronological appearance of Wolfram syndrome symptoms. DM = 
diabetes mellitus, OA = optic atrophy, DI = diabetes insipidus, D = deafness, Renal = 
renal tract abnormalities, Ataxia = neurological abnormalities (reproduced from Barrett 
and Bundey, 1997). 
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The vast majority of Wolfram syndrome cases arise as a result of homozygous or 
compound heterozygous mutations in the gene encoding Wolfram syndrome-1 (WFS1, 
Wolframin) on the short arm of chromosome 4. WFS1 was identified independently by 
two groups 119, 120. However, a small percentage of Wolfram syndrome patients have 
mutations in the gene encoding WFS2 (CDGSF iron sulfur domain-2, CISD2), on the 
long arm of chromosome 4 121, 122. Wolfram patients with mutations in the Wfs2 gene do 
not develop diabetes insipidus, but have profound gastrointestinal ulceration and bleeding 
122. Interestingly, there have been a few case reports linking Wolfram syndrome to 
deletions of mitochondrial DNA (mtDNA), but the cause of the association is unknown 
123. 
Examination of various tissues demonstrates that WFS1 mRNA is expressed in 
almost all adult tissues, with highest expression found in the brain and pancreas 124. 
WFS1 protein localizes to the ER as a multi-pass transmembrane protein, with the C-
terminal and N-terminals located in the ER lumen and cytoplasm, respectively 125, 126. The 
expression of WFS1 is increased following induction of ER stress and is cooperatively 
regulated by IRE1 and PERK signaling 127, 128. One goal of increasing WFS1 protein 
content in the cell during the UPR is in the restoration of ER homeostasis since WFS1 
functions in a negative feedback loop, exerting an inhibitory effect on XBP-1 and ATF6 
129. In Wolfram syndrome, loss of WFS1 function in  cells renders them susceptible to 
chronic hyperactivation of the UPR, leading to  cell dysfunction and apoptosis. Mice 
harboring a pancreatic  cell-conditional Wfs1 gene deletion display induction of ER 
stress markers, fewer secretory vesicles, with enhanced apoptosis and reduced overall 
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pancreatic  cell mass 130. These observations suggest that WFS1 protein counteracts ER 
stress and mutations in Wfs1 gene in Wolfram syndrome shifts the equilibrium of ER 
homeostasis, initiating persistent UPR activation, resulting in  cell pathology. 
A recent report by Hatanaka et al (2011) revealed that the WFS1 protein also 
localizes to insulin secretory granules of pancreatic  cells. The authors reported the role 
of WFS1 in granular acidification, insulin processing and secretion 131. Since insulin 
secretion in response to glucose stimulation is the hallmark of the  cell, this discovery 
further highlights the potential dysfunction that may ensue in the absence of functional 
WFS1 protein (Figure 1.6). 
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Figure 1.6: Roles of WFS1 in the pancreatic β cell. WFS1 protein expression is 
increased by ER stress and performs a number of functions in the β cell: (1) WFS1 on the 
ER membrane regulates ATF6 expression to alleviate UPR activation and restore 
homeostasis, (2) WFS1 co-regulates the expression of AATF, preventing apoptosis, and 
(3) the presence of WFS1 on secretory granules permits granular acidification required 
for insulin maturation.  
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1.11. Mutations leading to Wolfram syndrome 
The Wfs1 gene encompasses 33.4kb of genomic DNA, transcribing as a 3.6kb 
mRNA that encodes the 890 amino acid WFS1 protein. The Wfs1 gene consists of eight 
exons, the first of which is non-coding. Exons 2-7 and most of the final and largest exon, 
8, encode the WFS1 protein. There are many mutations in the Wfs1 gene that result in 
Wolfram syndrome. These mutations, which number over one hundred, are distributed 
over the entire gene and include missense mutations, frameshifts, and amino acid 
deletions and insertions (Figure 1.7). 
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Figure 1.7: WFS1 structure and mutations. Hypothetical structure of WFS1 based on 
hydrophobicity/hydrophilicity plots of the amino acid sequence, showing nine predicted 
transmembrane domains. Mutations include nonsense, missense, deletions and insertions 
(reproduced from Khanim et al (2001)). 
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1.12. Allelic polymorphisms of WFS1 as a diabetes risk factor 
 Recently, genome-wide association studies (GWAS) have successfully revealed 
susceptibility genes for T2DM. Some of these genes include the E23K variant of the K+ 
inwardly-rectifiying channel subfamily J, number 11 (KCNJ11), the peroxisome 
proliferator-activated receptor-γ (PPARG) P12A variant, and the transcription factor 7-
like 2 (TCF7L2) genes133-137. However, the candidate-gene approach is also effective to 
identify those genes that confer susceptibility to common diseases. Since WFS1 
mutations lead to Wolfram syndrome and DM is one of the major features of this 
syndrome, there have been a number of studies investigating if allelic variants in WFS1 
could be lead to increased susceptibility for T1DM or T2DM progression.  
 The first candidate-gene report by Awata et al (2000) focused on the possible 
contribution of allelic variations in WFS1 as a non-autoimmune genetic basis for T1DM 
susceptibility. The authors identified four common missense mutations (R456H, G576S, 
H611R, and I720V) in WFS1, with the R456H, H611R, and I720V alleles being strongly 
associated with T1DM. The association of WFS1 alleles with T2DM is even stronger. 
Minton et al (2002) studied five non-synonomous SNPs encoding distinct amino acid 
changes in the UK population and found that the R-allele at residue 456 and the H-allele 
at residue 611 were over-transmitted to T2DM-affected offspring. Furthermore, they 
reported that the H611 allele is present in more T2DM than control individuals, strongly 
suggesting that the WFS1-R611 allelic variant was protective from T2DM progression. 
This finding was confirmed in a separate study focusing on Japanese T2DM patients 140. 
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Non-coding SNPs in WFS1 have also been strongly associated with T2DM; however, 
likelihood ratio test suggest that the H611R allele is the functional variant explaining the 
association 141. A Swedish study found borderline statistical significance for R611 with a 
reduced risk for T2DM 142. Interestingly, Florez et al (2008) suggested that WFS1 allelic 
variants may confer a protective role through an improvement in β cell function. Indeed, 
they proposed that the R611 allele homozygotes demonstrated higher insulinogenic 
indices 143. In accordance with this observation, Chistiakov et al (2011) showed the 
protective role of R611 amongst other SNPs against T2DM in a Russian population. 
Furthermore, the authors demonstrated that the R-611 was evolutionary conserved by 
multiple pairwise alignment of the human WFS1 protein sequence with primates and 
rodents 144. 
 Thus, allelic variation in WFS1 may alter the risk for development of DM. Since 
WFS1 functions in the β cell to alleviate ER stress by counteracting chronic UPR 
activation, promote anti-apoptotic behavior, and increase intravesicular insulin 
maturation, it seems fitting that allelic variants of WFS1 could induce β cell dysfunction 
and fragility, accelerating the development of DM. 
 
1.13. Adaptive alterations to WFS1 deficiency 
In humans with Wolfram syndrome, the chronological appearance of clinical 
symptoms has been well characterized (Figure 1.4). For the onset of DM, the tender age 
of six is the median, indicating that pancreatic β cell mass has slowly degenerated over 
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the course of years due to the loss of functional WFS1 protein. It is quite likely that β 
cells undergo adaptive changes in gene expression in order to maintain insulin secretion 
during chronic UPR activation. In addition, WFS1 deficiency may signal an alteration in 
the expression of microRNA as a compensatory response. 
However, mouse models of Wolfram syndrome do not accurately recapitulate the 
human disease. The mice display progressive glucose intolerance with insulin deficiency, 
consistent with diabetes 130. Nevertheless, the diabetic phenotype is not strong due to the 
persistence of islets despite the absence of WFS1 protein. Animal models are not perfect 
for examining human disease due to their increased metabolic rates and differences in 
gene number and expression. The incomplete phenocopy of the disease in mouse models 
highlights the possibility that the surviving pancreatic β cells have somehow adapted to 
the absence of WFS1 by altering the expression of distinct genes or genetic regulators. 
 
1.13.1. MicroRNA 
MicroRNAs (miRNAs) are small, noncoding, 21-23 nucleotide RNA molecules 
that impact gene expression through post-transcriptional regulation 145, 146. Initially, 
miRNA were discovered in Caenorhabditis elegans in 1993 147, 148. Functionally, miRNA 
are specific gene silencers that base pair with the 3‟ untranslated region (UTR) of target 
mRNA, leading to the inhibition of translation or affecting mRNA stability and 
degradation 146, 149. 
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In the β cell, there are a number of active miRNA that control insulin content and 
secretion. Most notably, miR-375 plays a negative role in glucose-stimulated insulin 
secretion 150. MiR-124a affects the expression of a number of genes in the β cell, 
including the transcription factors FoxA2 and Pdx1, secretory protein SNAP25 and 
Rab3a, and ion channels Kir6.2 and Sur1 151, 152. Recently, the list of β cell-active 
miRNAs includes miR-130a, miR-200, and miR-410, which have been shown to be 
involved in the regulation of insulin secretion 153. Melkman-Zehavi et al (2011) reported 
that knockdown of miR-24, miR-26, miR-182, or miR-148 lead to the downregulation of 
insulin promoter activity and insulin mRNA levels. 
In relation to ER stress, there are a few miRNAs reported to date. Behrman et al 
(2011) demonstrated the ER stress-mediated induction of miR-708. Interestingly, the 
expression of miR-708 was regulated by the ER stress-induced transcription factor 
CHOP. The sequence for miR-708 is embedded within an intron of the CHOP-regulated 
gene Odz4, such that Odz4 and miR-708 are co-regulated by CHOP. The authors 
demonstrated that miR-708 targets rhodopsin mRNA and suggested that the induction of 
miR-708 is an additional mechanism in the UPR to decrease protein influx into the ER in 
an attempt to restore ER homeostasis 155. In a similar manner, the UPR-related 
transcription factor XBP-1 induces the expression of miR-346, which targets transporter 
1 (TAP1), decreasing the ER load 156. There are also a number of ATF6-controlled 
miRNAs, including miR-455, whose suppression by ATF6 permits translation of its 
target mRNA, calreticulin, an ER chaperone involved in restoring ER homeostasis 157. In 
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addition, modulation of the UPR by decreasing the expression of XBP1 is the goal of the 
PERK-induced miR-30c-2-3p 158. 
It is clear that miRNA play a prevalent role in β cell function. With the 
identification of an ER stress-related miRNA, it is tempting to propose that β cells in 
Wolfram syndrome, which are undergoing chronic ER stress conditions, may have 
altered the expression profile of distinct miRNAs as compensatory survival mechanisms. 
 
SIGNIFICANCE OF STUDYING WFS1 AND ER STRESS FOR DIABETES 
As outlined above, the subtypes of diabetes are delineated based on their 
pathogenic mechanism leading to hyperglycemia. However, it is the functional state of 
the pancreatic  cell and the critical  cell mass within the pancreas that defines whether 
blood glycemia can be regulated. During the development of diabetes,  cell dysfunction 
and reduced  cell mass accelerate the progression (Figure 1.7). Since ER stress and UPR 
activation are inherent features of the  cell, it is not surprising that disturbance of ER 
homeostasis can lead to  cell dysfunction and death, and hence, reduction in the  cell 
mass (Figure 1.8) 
Given the fact that ER stress is elevated and the UPR is chronically activated 
during the pre-diabetic phase, it may be possible to study this association with two goals 
in mind. First, examining the role of ER stress-regulating genes, such as WFS1, in 
maintaining  cell viability may lead to the identification of unique compounds or 
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signaling pathways that promote  cell survival. In current diabetic treatment, weight-
loss, bariatric surgery, and dietary modifications have the potential to reverse diagnosis of 
diabetes. In contrast, diabetic medications attempt to extend the function and number of 
the remaining  cell mass without alleviating the underlying condition. The outcome of 
this first research goal would be to develop an ER stress-mitigating therapy that would 
alleviate ER stress in  cells during the pre-diabetic phase with the hope of prolonging  
cell viability and preventing  cell loss. Ultimately, this would delay or prevent diabetes 
progression.  
Second, exploring the association of chronic ER stress and  cell viability may 
lead to the discovery of biomarkers of ER stressed  cells. Currently, the pre-diabetic 
phase is screened by periodic assessment of blood glucose and glycosylated A1C levels. 
These clinical readings, while useful is predicting and diagnosing diabetes, do not 
directly assess the functional state of the  cell. Whether ER stress in  cells leads to the 
release of distinct biomarkers is unknown, but it remains a possibility. The potential 
advantage of determining the functional state of an individual‟s  cells months-to-years 
prior to hyperglycemic readings as a result of severely diminished  cell mass would be 
extremely beneficial. Biomarker screening for ER stressed- cells would permit the use 
of ER stress-regulating chemical or biological compounds to restore  cell function and 
maintain  cell mass, preventing diabetes progression. 
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Figure 1.8: The therapeutic and biomarker potential of the ER stress pathway in 
diabetes. ER stress level fluctuates in the pancreatic  cell as a physiological response to 
the increased demand of insulin biosynthesis and exposure to blood-borne nutrients. 
During diabetogenesis, elevated ER stress contributes to pancreatic  cell loss. The 
remaining  cells have increased workload, thus pushing ER stress conditions to much 
higher levels. Examination of ER stress and UPR activation in  cells may reveal novel 
pre-diabetic biomarkers that indicate the  cell mass is (1) undergoing chronic ER stress 
or (2) dramatically diminished prior to clinical diabetes onset. The ability to modulate ER 
stress levels in  cells by chemical or biological compounds may lead to maintenance of 
 cell mass such that diabetes onset is prolonged or prevented. 
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CHAPTER II 
ALLELIC VARIANTS OF WFS1 GENE CONTRIBUTE TO PANCREATIC BETA 
CELL VIABILITY BY UPREGULATION OF NETRIN-1 EXPRESSION 
 
SUMMARY 
Wolfram syndrome is a rare disease characterized by juvenile-onset, non-
autoimmune diabetes mellitus and progressive optical atrophy. The vast majority of 
Wolfram patients have mutations in the Wfs1 gene. The roles of WFS1 protein in the 
pancreatic β cell include the maintenance of ER homeostasis through the regulation of 
ATF6 signaling and secretory granule acidification 128, 129, 131, 159. In addition to the 
numerous mutations that lead to the development of Wolfram syndrome, the Wfs1 gene 
has also been associated with low-frequency sensorineural hearing loss and psychiatric 
symptoms. Genome-wide association studies and candidate gene studies have lead to the 
association of Wfs1with increased risk for development of T2DM 138-143, 160-164. In 
particular, the SNP, H611R, has been linked with T2DM. 
In this chapter, the two allelic variants histidine (H) and arginine (R) at amino 
acid residue 611 of WFS1 were compared. It was determined that while expression of 
both alleles lead to an increase in both cell viability and insulin secretion, the minor 
allele, R611, had an increased cytoprotective role. Gene expression comparative study of 
the alleles revealed that netrin-1 signaling was increased following WFS1 expression and 
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that the protective WFS1-R611 allelic variant increased the expression of netrin-1 to a 
greater extent. Netrin-1 has been previously reported to play a role in pancreatic 
morphogenesis and protection of β cells from hyperglycemia-induced apoptosis 165-167. 
These data collectively suggest that in addition to the reported roles of WFS1 in 
alleviation of chronic UPR conditions and involvement in secretory granule acidification 
and insulin maturation, WFS1 also maintains pancreatic β cell survival through the 
increase in Netrin-1 signaling. 
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INTRODUCTION 
During the pre-diabetic phase of diabetogenesis, there is a profound reduction in 
pancreatic β cell mass. Whether this decrease is mediated by β cell apoptosis or loss of 
lineage fidelity, induction of ER stress and UPR activation is among the list of 
contributory factors. The necessity to maintain normoglycemia imparts increased burden 
on the residual β cells to manufacture sufficient insulin to regulate blood glucose. 
Increased demand of amplified insulin synthesis exhausts the folding capacity of the ER 
of the remaining β cells, leading to chronic ER stress and UPR activation. There are 
currently no known pharmaceutical options to alleviate ER stress in the β cell as a 
therapeutic approach to maintain β cell viability and stave off β cell loss.  
As outlined in the introductory chapter, deficiency of WFS1 protein leads to 
chronic ER stress and hyperactivation of the UPR in pancreatic β cells, culminating in β 
cell dysfunction and death, and promotes the pathogenesis of DM in Wolfram syndrome. 
WFS1 functions in a number of roles in the β cell, depending on its location and the 
functional state of the β cell. As an integral ER membrane protein, WFS1 expression is 
increased by ER stress and is involved in maintaining the homeostatic balance of the ER 
through the degradation of ATF6 128, 129. In addition, WFS1 controls the expression of the 
anti-apoptotic factor AATF 159. More recent evidence indicates that WFS1 also localizes 
to secretory vesicles in pancreatic β cells where it promotes insulin maturation and 
secretion 131.  
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In Wolfram syndrome, it is the loss of functional WFS1 protein that causes ER 
stress, chronic UPR activation and β cell death. Thus, Wolfram syndrome has been used 
as a prototype to study chronic ER stress conditions and UPR hyperactivation in the 
pancreatic β cell. Since the presence of WFS1 is necessary to maintain β cell viability and 
prevent dysfunction, the augmentation of WFS1 expression in pre-diabetic β cells may 
protect against ER stress, prevent β cell dysfunction and death, such that the β cell mass 
would be maintained. 
There are a myriad of mutations in WFS1 that engender Wolfram syndrome. The 
online repository maintained by the Kresge Hearing Research Institute at the University 
of Michigan lists two hundred and twenty-five mutations in the Wfs1 gene, which 
encompasses one hundred and seventeen base substitutions, seventy-seven deletions and 
thirty-one insertions. The database also reveals a total of one-hundred and forty-three 
single nucleotide polymorphisms (SNPs) in Wfs1, including sixty-one synonymous, fifty-
one non-synonymous, two insertions, and twenty-nine non-coding polymorphisms 168. 
Genomic population studies investigating the involvement of genes and their 
polymorphisms on diabetes risk have suggested that a number of SNPs in WFS1 are 
associated with increased T2DM risk. Some of these SNPs are non-coding and their 
association may be due to the co-segregation with other mutations. One of the SNPs, 
rs734312, involving a histidine-to-arginine substitution at amino acid position 611 
(H611R) is strongly linked to T2DM 138-143, 160-164. However, genome-wide association 
studies includes a plethora of confounding factors including the wide genetic variation of 
the populations studied in addition to diverse environmental and metabolic conditions. 
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Thus, direct comparison of the allelic variants at position 611 in a cell line may reveal the 
protective nature of the R611 allelic variant. 
The precise location of the amino acid at position 611 of the WFS1 protein in 
relation to the ER membrane, lumen and cytoplasm is not known. Hypothetical models of 
the structure of WFS1 vary in the positioning of the predicted nine transmembrane 
domains. In the model proposed by Khanim et al (2001), residue 611 lies within the ER 
membrane as part of the eighth transmembrane domain (Figure 1.5). However, an 
alternative structure suggested by Alimadadi et al (2011) reveal the location of residue 
611 in a cytoplasmic loop between the eighth and ninth transmembrane-spanning regions 
(Figure 2.1). The location and function of a particular amino acid may be intimately 
linked: the location may affect function. The substitution of a particular amino acid that 
occurs as a result of a polymorphism may affect both location of the protein and function 
of the protein. In the WFS1 protein at position 611, the major allelic variant is histidine 
(H), a positively-charged, aromatic amino acid. Histidine has a pKa of 6.5, which enables 
easy protonation/deprotonation of the imidazole sidechain at the physiological pH range 
of the cytoplasm (pH 7.4) and the ER (pH 7.2). This flexibility permits histidine to 
alternate between embedding within the hydrophobic protein core and being exposed to 
the environment. For this reason, histidine residues are often in the active or binding sites 
of a protein. Arginine (R), like histidine, is a positively-charged, polar amino acid. The 
high pKa value of 12.5 imparts a positive charge on the guanidium group of arginine at 
all pH ranges, leading to arginine’s preference to be on the surface of a protein. Arginine 
forms salt-bridges with negatively-charged amino acids, increasing the stability of 
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proteins. Thus, substitution of histidine for arginine at residue 611 may alter the local 
structure and/or function of WFS1. There are a number of reported histidine-arginine 
substitutions that lead to various diseases; examples include the H209R substitution in the 
insulin receptor protein causing Donohue syndrome 170, the H65R change in proinsulin 
leading to familial hyperproinsulinemia 171, and R311H in the c-erbA beta thyroid 
hormone receptor in pituitary resistance to thyroid hormones 172. Thus, it is possible that 
the histidine-to-arginine substitution in WFS1 may alter its function. 
In this chapter, the polymorphic variants at position 611 of the WFS1 protein are 
compared in their relation to β cell function and viability. The findings reveal that 
augmentation of WFS1 expression leads to an increase in both cellular insulin content 
and glucose-induced insulin release. In addition, WFS1 increases the viability of β cells 
when challenged by an ER stress agent, with the WFS1-R611 allele have a stronger 
effect. To further compare the alleles, gene microarray analysis was performed on cell 
lines expressing each allelic variant. The results of this analysis indicated an increase in 
netrin-1 signaling in both allelic variants, with the T2DM-protective arginine variant 
having greater induction of netrin-1 expression. 
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Figure 2.1: Hypothetical structure of WFS1protein. Hypothetical structure of WFS1 
based on transmembrane protein display software (reproduced from Alimadadi et al 
(2001)). 
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MATERIALS AND METHODS 
Cell Culture 
The rat insulinoma cell line, INS-1 832/13, was generously provided by 
Christopher Newgard (University of Texas Southwestern Medical Center, Dallas, TX). 
To generate doxycycline-inducible gene expression, INS-1 832/13 cells had been 
transduced with a lentivirus bearing the tetracycline repressor construct by Shinsuke 
Ishigaki; these cells are termed “INS-1” or “control”). INS-1 cells were cultured in RPMI 
1640 medium containing 10% Tetracycline-free FBS, 1% Pen/Strep, 0.1% β-
mercaptoethanol, and 1% sodium pyruvate. Doxycycline-inducible WFS1-WT (H611)-
expressing INS-1 cells had been previously established by Shinsuke Ishigaki; these cells 
are termed “WFS1-WT”. To generate INS-1 cells expressing doxycycline-inducible 
WFS1-R611, a lentivirus containing human WFS1-R611-FLAG was transduced into 
INS-1 832/13 cells stably expressing the tetracycline repressor, pTetR. Transduced cells 
were selected by incubation in 2 µM Puromycin for fourteen days; these cells are termed 
“WFS1-R611”. To induce WFS1 expression, WFS1-WT and WFS1-R611 cells were 
cultured in 1 µg/mL doxycycline in 5mM RPMI medium for 48 hr prior to protein/RNA 
isolation. 293FT cells were maintained in DMEM containing 10% FBS, 1% Pen/Strep, 
1% MEM-NEAA, 1% Glutamate, 1% Sodium pyruvate and 1% G418. G418-free 
medium was used for lentiviral production. 
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Lentiviral Plasmid Construction 
Plasmids used for lentiviral-mediated expression included pENTR1A-noccDB, 
pLenti-CMV/TO Puro, pEF-ENTRA, and pLenti CMV-GFP, generously supplied by Eric 
Campeau (UMass Medical School, Worcester, MA) or purchased from Addgene 
(Cambridge, MA). The WFS1-R611 allelic variant was generated by mutagenesis of 
pENTR1A-hWFS1-WT (H611) using the PCR-based KOD-Plus Mutagenesis Kit 
(Toyobo, Osaka, Japan) and the following primer pairs: WFS1-H611R-F2: 5’-
gctggtggaccaaggccagcttc-3’ and WFS1-H611R-Rev: 5’gcaacagcaggggcacactacagac-3’. 
The LR clonase recombination reaction was used to introduce the WFS1-R611 cassette 
into the pLenti CMV/TO Puro plasmid for inducible expression. For constitutive and 
traceable expression of either WFS1 allele, the WFS1 gene sequences were transferred by 
restriction digest and ligation into the pEF-ENTRA plasmid. LR clonase recombination 
transferred the EF-WFS1 cassettes into pLenti CMV-GFP to generate pLenti-CMV/GFP-
EF1α-hWFS1-H611 (or R611). 
 
Lentiviral Generation, Titration and Transduction 
Plasmids used for lentiviral generation included pLP1, pLP2, and pVSVg kindly 
given by Michael Green (UMass Medical School, Worcester, MA). Lentiviral generation 
involved the transfection of 293FT cells (Invitrogen, Carlsbad, CA) with the packaging 
plasmids (pLP1, pLP2, pVSVg) and the specific lentiviral vector (pLenti-) of choice 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Virus-containing supernatant was 
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harvested after 48 and 72 hour durations, centrifuged at 1500rpm for 5min to pellet 
cellular debris and filtered through 0.45µm filter system. The viral supernatant was 
subsequently ultracentrifuged at 25000rpm for 2hr at 4°C. Supernatant was decanted into 
bleach and the lentiviral pellets were air-dried for < 5min. Lentiviral pellets were 
resuspended in 100µl medium, aliquoted as 25µl samples and stored at -80°C. Titration 
of lentivirus was performed by transducing 293FT cells with 10-fold serial dilutions of 
the lentivirus. 
 
Immunoblotting 
INS1-832/13 cells were lyzed in a solution of M-PER (Pierce, Rockford, IL) 
containing protease inhibitors (Sigma, St. Louis, MO) and phosphatase inhibitors (Roche, 
Indianapolis, IN) by repeated freeze-thaw cycles, followed by centrifugation at 
10,000rpm for 15min to pellet DNA and insoluble material. Protein lysate concentrations 
were determined using Nanodrop (Thermo Fisher Scientific, Waltham, MA) and 30-50 
µg protein were separated using a 4-20% gradient SDS-PAGE (BioRad, Hercules, CA). 
Proteins were transferred to PVDF membrane (Millipore, Billerica, MA), blocked with 
5% non-fat dry milk, and probed with specific primary antibodies. After washing and 
secondary antibody incubations, proteins on the membranes were visualized using ECL 
(Amersham Piscataway, NJ). Antibodies included anti-FLAG M2 (Sigma, St.Louis, 
MO), anti-WFS1 (Origene, Rockville, MD), and GAPDH (Cell Signaling Technology 
Inc., Danvers, MA). 
52 
 
Flow-assisted Cell Sorting (FACS) 
Parental INS-1 832/13 TetR (INS-1), WFS1-WT, and WFS1-R611 cells were 
plated out onto 24-well plates and cultured in 5mM culture medium in the presence or 
absence of 1µg/mL doxycycline for 48 hours. After 24 hour in culture, selected wells 
were treated with 5nM thapsigargin (TG) for remaining 24 hours. Next, propidium iodide 
was added to medium for 10min to stain apoptotic cells. Cells were then washed twice in 
PBS and collected by trypsinization, centrifugation and resuspension in 1mL PBS 
containing Mitoprobe (Invitrogen). Cells in suspension were transferred to FACS tubes 
and read on a multicolor BD LSR II flow cytometer (BD Biosciences). Data was 
analyzed using FlowJo software version 7.6.3 (Treestar Inc., San Carlos, CA). 
 
Glucose-stimulated Insulin Secretion (GSIS) 
Cells (INS-1, WFS1-WT, and WFS1-R611) were counted and plated at 100,000 
cells/ well on 24-well plates and cultured in 5mM glucose RPMI medium the presence or 
absence of 1µg/mL doxycycline for 48 hours. On the day of experiment, medium was 
aspirated and cells were washed twice with 1X PBS. The cells were then incubated in 
0.5mL Kreb’s Ringer Buffer (KRB: 135mM NaCl, 3.6mM KCl, 10mM Hepes, pH7.4, 
5mM NaHCO3, 0.5mM NaH3PO4, 0.5mM MgCl2, and 1.5mM CaCl2) devoid of glucose 
for 30min. Next, 0mM KRB was aspirated and cells were incubated in 1mL KRB 
containing 2.5mM glucose for 1 hour at 37°C to bring the cells to baseline. Next, the 
2.5mM-KRB was removed and the cells were washed 2X with PBS. Finally, 0.8ml KRB 
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containing 3mM or 15mM glucose, with or without other secretagogues, was added for 1 
hour at 37°C. The supernatant from each well was harvested, centrifuged at 1500rpm for 
5 min to remove cellular debris, transferred to microfuge tubes and stored at -80°C. To 
extract cellular insulin, 0.5mL of acidifed ethanol (1.5% concentrated HCL, 23.5% water, 
75% ethanol) was added to each well. The plates were wrapped in parafilm and stored 
overnight at -20°C. Following day, 0.5mL normalization buffer (1M Tris, pH 7.4) was 
added to each well and mixed on a plate shaker for 10min. The supernatant was collected, 
centrifuged to pellet cellular debris and 900 µL was transferred to microfuge tubes and 
stored at -80°C. Insulin ELISA was performed using rat insulin kit (ALPCO Diagnostics, 
Salem, NH). ELISA plates were analyzed on a plate reader using Softmax Pro software 
version 5.0 for Windows (Molecular Devices Corporation, Sunnyvale, CA). 
 
DNA microarray 
INS-1, WFS1-WT, and WFS1-R611 cells were plated at a density of 500,000 
cells/ well on 6-well plates and cultured in 5mM glucose RPMI medium supplemented 
with 1µg/mL doxycycline for 48 hours. Cells were harvested by trypsinization, 
centrifuged and washed with 1X PBS. Wells were resuspended in 600µL RLT buffer 
containing β-mercaptoethanol (10µ/mL). Total RNA was isolated using RNeasy mini kit 
(Qiagen, Valencia, CA). Microarray analysis was performed on triplicate RNA samples 
of doxycycline-treated INS-1, WFS1-WT, and WFS1-R611 cells using Genechip Rat 1.0 
ST array (Affymetrix, Santa Clara, CA). DNA microarray was performed by the Genome 
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Technology Core at the Whitehead Institute, Cambridge, MA. Microarray data was 
analyzed by biostatisticians in the Program in Gene Function and Expression at UMass 
Medical School, Worcester, MA. 
 
Real-Time Qualitative Polymerase Chain Reaction (qPCR) 
Total RNA was isolated using RNeasy Mini kit (Qiagen, Valencia, CA) and 
cDNA was generated by reverse transcription of 1µl of total RNA with Oligo-dT primer. 
Triplicate qPCR samples were analyzed using the iQ5 system (BioRad, Hercules, CA) 
with the general program: 95°Cfor 10min, 40 cycles of 95°C for 10sec and 55°C for 
30sec. The relative expression of each transcript was determined by a standard curve of 
cycle thresholds for serial dilutions of cDNA and normalized to the expression of actin. 
Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and the 
following primers were used for real-time PCR: rat actin: gcaaatgcttctaggcgac and 
aagaaagggtgtaaaacgcagc; rat BiP:, tgggtacatttgatctgactgga and 
ctcaaaggtgacttcaatctggg; rat CHOP, agagtggtcagtgcgcagc and ctcattctcctgctccttctcc; rat 
spliced XBP-1, tggccgggtctgctgagtccg and atccatgggaagatgttctgg; rat INS2, 
atcctctgggagccccgc and agagagcttccaccaag; and rat WFS1:  atcgacaacagcgccgc and 
gcatccagtcacccaggaag, Netrin-1: gcttccaaaggaaaactgaa and cttccaccagtcccctgctt; 
Unc5a: ggcagatcttccagctcaac and tagcttctgccggataggaa; and DCC: 
ttcggagcaggaagaactgt and cacaggctgtagggatggtt. 
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Statistical Analysis 
Statistics on data from FACS and GSIS included one-way ANOVA with 
Bonferroni’s post-test and was performed using the Graphpad Prism version 5.04 for 
Windows (Graphpad Software, La Jolla, CA. www.graphpad.com).  
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RESULTS 
Exogenous expression of WFS1 protects INS-1cells from ER stress-mediated cell death 
Mutations in the Wfs1 gene lead to the development of Wolfram syndrome 118, 119. 
Recent findings report that Wfs1 may be a candidate gene for T2DM development. A 
number of reports have suggested specific single nucleotide polymorphisms in Wfs1that 
may alter the susceptibility to the development of T2DM 138-143, 160-164. Functional 
characterization and analysis of allelic variants would reveal the true impact of these 
alleles on β cell survival and function. 
To demonstrate that the on-demand exogenous expression of allelic variants of 
WFS1 following doxycycline treatment, an immunoblot probing for WFS1 was 
performed. The predicted size of WFS1 protein is approximately 100 kiloDalton (kDa). 
As shown in Figure 2.2a, WFS1 protein was increased following doxycycline treatment. 
In addition, it was noted that the previously-reported oligomeric forms of WFS1 at 
roughly 200 and 300 kDa were also observed 126. However, the level of WFS1-R611 
expression was not consistent with that of WFS1-WT (Figure 2.2b) possibly due to lower 
titers of infectious lentivirus used to generate the WFS1-R611 cell line. 
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Figure 2.2: Induction of WFS1 expression in INS-1 cell lines. INS-1 832/13 cells 
containing the expression tetracycline repressor (TetR) gene were transduced with 
lentivirus bearing WFS1-WT (H611) or WFS1-R611 alleles and selected for positive 
cells with puromycin. (a) WFS1 is induced by incubation with doxycycline. (b) 
Comparison of expression of WFS1-WT and three cell lines of WFS1-R611 shows that 
the expression level of the latter allele was lower at the same concentration of 
doxycycline. 
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Using the doxycycline-inducible WFS1-WT or WFS1-R611 cell lines, the 
potential of these alleles to protect against cell stress was examined. Cell viability was 
assessed by determining mitochondrial activity with Mitoprobe and propidium iodide 
(PI), to determine apoptosis and assessed by flow cytometric analysis. As shown in 
Figure 2.3a, flow-assisted cell sorting (FACS) could identify those cells with decreased 
mitochondrial potential and/or increased PI staining. Cells treated with thapsigargin (TG) 
had increased percentage of cells with lower mitochondrial potential (control: 6.21% vs. 
TG: 24.3%). The number of cells with positive PI staining also increased in TG-treated 
cells compared to control cells (control: 8.53% vs. TG: 10.7%). When WFS1 expression 
was induced by addition of doxycycline, the percentage of cells with lower mitochondrial 
activity (“Mitoprobe-low”) and positive PI staining were dramatically reduced (compared 
to Dox(-), TG-treated cells), indicating a protective effect of WFS1 expression. 
In WFS1-WT and WFS1-R611 cells, treatment with the ER stress-inducing agent 
thapsigargin lead to a dramatic increase in the “Mitoprobe-low” population of cells 
(Figure 2.3b and c, respectively). Following induction of WFS1-WT expression, there 
was a significant decrease in the “Mitoprobe-low” percentage of cells, reflecting 
protection from TG-mediated stress in these cells. In a similar manner, expression of 
WFS1-R611 had a protective effect against TG-mediated cell stress. However, the 
protective response with WFS1-R611 expression was greater than that for WFS1-WT. 
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Figure 2.3: WFS1 expression protects against ER stress-mediated cellular 
dysfunction and death. (a) Flow-assisted cell sorting allowed calculation of 
“Mitoprobe-low” and “PI-positive” cells following WFS1 expression and TG-treatment. 
(b) WFS1-WT expression in INS-1 cells protects cells from TG-mediated cell death. (c) 
Expression of WFS1-R611 demonstrated a statistically significant protective effect 
against TG-mediated apoptosis. 
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Augmentation of WFS1 expression increases insulin production and secretion 
 WFS1 deficiency in Wolfram syndrome leads to progressive β cell loss as a result 
of chronic ER stress and UPR hyperactivation. In addition, using the β cell-specific Wfs1 
knockout mouse, Riggs et al (2005) demonstrated impaired glucose-stimulated insulin 
secretion. The subcellular localization of WFS1 on secretory granules in β cells further 
highlights the importance of WFS1 to β cell function. Thus, the augmentation of WFS1 
expression in β cells may further enhance their response to glucose challenge. 
 To analyze the effect of WFS1 augmentation on insulin secretion, INS-1 832/13 
cells with doxycycline-inducible expression of each WFS1 allele (WFS1-WT and WFS1-
R611) were grown in the presence or absence of doxycycline. Glucose-stimulated insulin 
secretion was performed and secreted and cellular insulin content was determined by 
ELISA. Induction of expression of either WFS1-WT or WFS-R611 leads to a dramatic 
increase in the cellular insulin content (Figure 2.4b, d). There was a slight and expected 
decrease in cellular insulin content following challenge with glucose. The secreted insulin 
content was also significantly elevated in those cells that had induction of WFS1 
expression when compared to non-induced cells (Figure 2.4a, c). These results 
demonstrate the profound effect that augmented WFS1 expression in the β cell has on 
insulin content and secretion stemming from the involvement of WFS1 in maintenance of 
ER homeostasis, insulin maturation and secretion. 
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Figure 2.4: Glucose-stimulated insulin secretion (GSIS) of WFS1-expressing INS-1 
cells. (a) INS-1 cells with augmented WFS1-WT expression secrete higher levels of 
insulin following challenge with 15mM glucose. (b) WFS1-WT expression increases the 
cellular insulin content. (c) WFS1-R611 cells secrete higher insulin when challenged with 
glucose. (d) WFS1-R611 cells contain increased cellular insulin content. (***, p<0.001). 
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Microarray data for WFS1 allelic variants 
In order to discern differences in gene expression between the two allelic variant 
of WFS1, a gene expression microarray was performed. WFS1 is not a transcription 
factor but augmented expression of WFS1 may indirectly alter the transcription of other 
genes. The microarray data revealed that the expression of many different genes was 
altered in both WFS1 variants. Due to the lower expression of the WFS1-R611 allelic 
variant, the number of genes identified by the microarray was significantly lower.  
Since WFS1 is involved in alleviation of ER stress, there was a wide array of ER 
stress/UPR related genes that were altered (Table 2.1). Of particular interest was the 
strong decrease in expression of the ER stress-related thioredoxin-interacting protein 
(TXNIP), the most highly upregulated gene in pancreatic β cells following exposure to 
hyperglycemic conditions 173. Other genes that were altered included those involved in 
ERAD (Derlin3, Herpud1, Fbxo6, Syvn1, and Os9) and ER chaperones (Dnajb9, Pdia2, 
Dnajc3, Pdia6, Pdia4, Dnajb4, Pdia5, Ero1lb, Ppil4, Ppil6, Fkbp11, and Hsp4l). In 
directly comparing the WFS1 alleles, the Derl3 gene was significantly increased 
following WFS1-WT expression, but decreased in cells with increased expression of the 
WFS1-R611 allele.  
Recently, WFS1 was localized to the secretory granules in β cells, where it is 
required for intragranular acidification, a necessary step for efficient insulin maturation 
and secretion 131. The results of the microarray revealed the alteration in a number of 
genes involved in secretion, including synaptotagmins (Syt12, Syt4, Syt2, Syt14, Syt15, 
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and Syt10), synaptic vesicle glycoproteins (Sv2b, Sv2c), and other secretion-related 
proteins (Scrn1, Rab27a, Vamp5, Snca, Trappc21, Snap23, Exoc3, and Synj2) (Table 
2.2). 
Since there was a notable difference between the protective effects of the WFS1 
alleles, the gene microarray data was examined to identify specific genes involved in cell 
viability or survival. One of the most interesting discoveries was the alteration of gene 
expression of those genes involved in netrin-1 signaling (Table 2.3). Netrin-1 (Ntn1) 
expression was increased in both WFS1-WT and WFS-R611 expressing cells, but to a 
greater extent in the latter allelic variant. There were also significant modifications in the 
receptors for netrin-1: Uncoordinated-5c (Unc5c) expression was increased by both 
WFS1 allelic variants and deleted in colorectal cancer (Dcc) expression was significantly 
diminished by both WFS1 variants. WFS1-WT also induced another netrin-1 receptor, 
Unc5b. These data propose a potential role of WFS1 in regulating netrin-1 signaling in 
the pancreatic β cell. 
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ER stress/UPR     
 Probe ID log(FC) p-Value Symbol 
WFS1-WT Up-regulated 
    10832487 2.229 7.06E-13 Derl3 
 10889766 1.694 2.56E-13 Dnajb9 
 10809328 1.642 8.13E-14 Herpud1 
 10895861 1.509 7.96E-11 Ddit3 
 10905453 1.390 1.67E-10 Kdelr3 
 10741723 1.340 8.00E-13 Pdia2 
 10847474 1.260 1.47E-09 Creb3l1 
 10856232 1.093 2.95E-12 Eif2ak3 
 10721865 1.072 3.24E-11 Ppp1r15a 
 10782028 1.028 2.11E-12 Dnajc3 
 10707824 0.995 3.32E-10 Sels 
 10892859 0.991 1.85E-10 Pdia6 
 10919996 0.990 4.62E-11 Manf 
 10808041 0.946 8.74E-12 Aars 
 10862361 0.903 1.45E-10 Pdia4 
 10773290 0.862 5.60E-09 Wfs1 
 10881583 0.846 3.78E-10 Fbxo6 
 10819787 0.837 1.03E-09 Dnajb9 
 10838823 0.817 6.86E-07 Chac1 
 20751498 0.792 3.41E-07 Pdia5 
 10799038 0.719 1.86E-09 Ero1lb 
 10701734 0.696 2.57E-08 Ppil4 
 10713160 0.672 3.64E-10 Syvn1 
 10830546 0.667 8.88E-08 Ppil6 
 10906934 0.624 4.03E-06 Fkbp11 
 10897760 0.618 1.36E-08 Atf4 
 10882111 0.615 3.66E-08 Rer1 
 10902892 0.597 5.44E-09 Os9 
WFS1-WT Down-regulated    
 10815099 -0.674 1.26E-09 Hspa4l 
 10884926 -0.711 5.69E-08 Ppil5 
 10857546 -0.828 1.50E-08 Itpr1 
 10885516 -0.862 5.44E-11 Eif2s1 
 10871582 -1.150 2.18E-10 Ppih 
 10817552 -3.970 2.46E-15 Txnip 
WFS1-R611 Up-regulated    
 10727260 0.920 5.76E-09 Ccnd1 
WFS1-R611 Down-regulated    
 10832487 -0.798 6.06E-08 Derl3 
 
 
 
 
Table 2.1: List of altered ER stress/UPR-related genes in WFS1-WT and WFS1-R611 cells 
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Secretion     
 Probe ID log(FC) p-Value Symbol 
WFS1-WT Up-regulated 
    10722830 2.521 9.20E-13 Sv2b 
 10820613 1.738 1.14E-10 Sv2c 
 10862634 1.275 9.18E-12 Scrn1 
 10911524 1.253 1.30E-09 Rab27a 
 10863215 1.249 3.61E-12 Vamp5 
 10816179 1.192 3.57E-11 Sh3d19 
 10862820 1.046 6.89E-11 Snca 
 10807140 1.032 2.05E-12 RGD621098 
 10716712 0.950 1.81E-10 Stxbp5 
 10808014 0.867 1.11E-10 Cog4 
 10870369 0.810 1.89E-08 Sgip1 
 10807609 0.767 2.52E-10 Vps4a 
 10727588 0.743 3.41E-09 Syt12 
 10803577 0.725 1.39E-08 Syt4 
 10764174 0.706 8.82E-07 Syt2 
 10939242 0.704 1.00E-08 Sytl4 
 10811947 0.700 1.04E-09 Exoc8 
 10808547 0.696 2.87E-09 Trappc2l 
 10821243 0.691 7.21E-10 Rab27a 
 10809459 0.680 2.02E-09 Trappc2l 
 10861268 0.670 2.34E-08 Cadps2 
 10940444 0.652 8.72E-10 Snap23 
 10929263 0.634 2.82E-09 Scg2 
 10936877 0.618 2.30E-08 Sytl5 
 10882111 0.615 3.66E-08 Rer1 
 10702453 0.595 7.85E-08 Exoc3 
WFS1-WT Down-regulated    
 10825120 -0.590 3.40E-08 Vps45 
 10710936 -0.658 1.89E-08 Doc2a 
 10810040 -0.737 4.36E-08 Syce2 
 10863757 -0.749 1.13E-09 Anxa4 
 10702829 -0.771 7.77E-10 Synj2 
 10738716 -0.867 1.40E-09 Arf2 
 10902232 -1.167 5.60E-10 Syt12 
 10711260 -1.591 1.83E-13 Trim72 
WFS1-R611 Up-regulated    
 10782590 2.918 1.04E-12 Synpr 
 10716880 1.262 1.80E-07 Stx11 
WFS1-R611 Down-regulated    
 10781361 -1.092 6.12E-09  Lgi3 
 10906364 -1.465 3.40E-10 Syt10 
 10711260 -1.486 3.96E-13 Trim72 
 
Table 2.2: List of altered genes related to the secretory pathway in cells with augmented 
expression of WFS1-WT or WFS1-R611. 
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Netrins     
 Probe ID log(FC) p-Value Symbol 
WFS1-WT Up-regulated 
    10833013 2.125 2.55E-14 Unc5b 
 10819469 2.069 2.65E-15 Unc5c 
 10743774 0.739 3.04E-07 Ntn1 
WFS1-WT Down-regulated    
 10805132 -0.593 4.94E-06 Dcc 
WFS1-R611 Up-regulated    
 10743774 2.472 3.04E-07 Ntn1 
 10819469 1.160 2.65E-15 Unc5c 
WFS1-R611 Down-regulated 
   
 10805132 -1.413 4.94E-06 Dcc 
 
 
 
 
 
Table 2.3: List of netrin-1 and netrin receptors with altered expression in WFS1-WT and WFS1-
R611 cells. 
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WFS1 augmentation induces the expression of netrin-1 
 To confirm the induction of netrin-1 expression, RNA from WFS1-WT and 
WFS1-R611 cells following doxycycline treatment was collected and used for 
quantitative PCR assessment of netrin-1. The data revealed that the expression level of 
netrin-1 in the control INS-1 cells was very low. Doxycycline-mediated induction of 
WFS1-WT expression in WFS1-WT cells leads to a dramatic increase in netrin-1 
expression (Figure 2.5). The fold change difference in expression of netrin-1 in WFS1-
WT cells was approximately 6 times when compared to the control INS-1 cells. In 
accordance with the microarray data, netrin-1 expression following induction of WFS1-
R611 protein was significantly higher than either INS-1 or WFS1-WT cells. In these 
cells, the fold expression increase in netrin-1 was 22-fold (Figure 2.5). 
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Figure 2.5: Confirmation of netrin-1 induction in INS-1 cells expressing either 
WFS1-H611 (WFS1-WT) or WFS1-R611 allelic variants. Control (INS-1), WFS1-
WT, and WFS1-R611 cells were plated and maintained in 5mM medium containing 
1µg/mL doxycycline to induce WFS1 expression. At 48 hours, RNA was harvested and 
used to determine the level of (a) netrin-1 and (b) Unc5c expression by qPCR using a 
BioRad iQ5 system. 
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DISCUSSION 
 In this chapter, the effect on pancreatic β cell function and viability following 
augmentation of WFS1 expression was examined. The results indicate that WFS1 
expression increases both cellular insulin content and glucose-stimulated insulin 
secretion, with no allele-dependent variation. Elevated WFS1 expression also increased 
the viability of pancreatic β cells exposed to ER stress-inducing conditions. Interestingly, 
the reported diabetes-protective R611 allele of WFS1 had a greater protective function 
when compared with the H611 allele. Gene expression analysis by microarray revealed 
increased netrin-1 signaling in both allelic variants. However, the expression was further 
amplified in the protective R611 allele. Based upon these findings, we propose that 
netrin-1 signaling provides an additional mechanism by which WFS1 promotes 
pancreatic β cell survival and β cell mass (Figure 2.6) 
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Figure 2.6: Role of WFS1-induced netrin-1 signaling in the pancreatic β cell. This 
chapter identified increased netrin-1 expression following augmentation of WFS1 
expression. Netrin-1 signaling has been demonstrated to be protective by preventing 
caspase-3 cleavage in β cells and is involved in the recruitment of pancreatic progenitor 
cells. WFS1-induced netrin-1 expression extends the role of WFS1 in the β cell and 
highlights why WFS1 allelic variation may contribute to β cell mass, and consequently, 
diabetes resistance.  
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ER stress can be induced in β cells by numerous physiological and pathological 
stimuli. Physiological activators of ER stress include increased demand for insulin 
secretion due to elevated blood glucose levels in the immediate postprandial period. 
Ingestion of food also exposes the β cell to amino acids and fatty acids, which trigger 
physiological ER stress. The term physiological ER stress implies that this is a normal 
event and UPR activation within the cell is a temporary event to facilitate the alleviation 
of ER stress, returning the ER to homeostasis, and maintaining the functional state of the 
β cell. However, pathological ER stress can also occur within the β cell. Exposure to 
chronic hyperglycemia or fatty acids, viral infection, or reactive oxygen species can 
precipitate pathological ER stress in the β cell. In this instance, there is unmitigated UPR 
activation such that ER homeostasis is not restored. Uncontrolled UPR activation leads to 
β cell dysfunction and apoptosis. 
WFS1 protein functions as part of the UPR where it controls the HRD1-mediated 
ubiquitination and proteasomal degradation of the UPR transducer ATF6 129. In addition, 
there is substantial crosstalk between WFS1 and the anti-apoptotic AATF 159. Thus, it can 
be postulated that augmentation of WFS1 expression would increase β cell survival. The 
results in this chapter demonstrate that the introduction of exogenous WFS1 into INS-1 
cells leads to the protection against ER stress-mediated apoptosis (Figure 2.3). There are 
a number of reports concerning the contribution of polymorphisms in the Wfs1 gene to 
risk for T2DM development 138-143, 160-164. These articles bring to attention the presence of 
a “protective” arginine at amino acid residue 611 in WFS1 (R611). Our data reveal that 
induced expression of the WFS1-R611 allele in INS-1 cells leads to greater protection 
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against ER stress-mediated cell death when compared to the “susceptible” WFS1-H611 
allele (Figure 2.2b). Pancreatic β cells are particularly sensitive to disturbances in ER 
homeostasis. WFS1 is a key molecule in regulating ER stress levels. Thus, elevated 
expression of WFS1, in particular the WFS1-R611 allele, in the fragile β cells would 
prevent hyperactivation of the UPR, permitting prompt restoration of ER homeostasis, 
and protect against β cell dysfunction or death.  
 A number of articles have assessed the contribution of each allele at residue 611 
in WFS1 to diabetogenic risk using the Homeostasis Model Assessment (HOMA) 
program, which estimates β cell function and insulin sensitivity as percentages of a 
normal reference population 174. Minton et al (2002) reported that WFS1-H611 
homozygotes had reduced, but not statistically significant β cell function. In another 
study, WFS1-R611 homozygotes were determined to have a higher insulinogenic index 
143. In support of these findings, another research group reported that the diabetogenic 
risk H611 allele of WFS1 conferred decreased insulinogenic index and lowered thirty 
minute serum insulin levels after oral glucose challenge in individuals with abnormal 
glucose regulation 160. However, in contrast to these findings, the data in this chapter 
reveal no significant difference in insulin secretion between the two allelic variants at 
residue 611 in WFS1. The previous population-based studies compared β cell function 
and found that the diabetogenic WFS1-H611 had decreased insulin release. However, this 
observation was not replicated in INS-1 cells expressing the allelic variants. Possible 
reasons for this discrepancy are the involvement of other co-segregating polymorphisms 
in WFS1 or other genetic modifiers in the population-based studies that affect insulin 
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secretion, which were not examined in the current research. Also, the whole-body 
assessment of β cell function by HOMA is very different to cell culture-based glucose-
stimulated insulin secretion studies. 
 In order to identify genes that may have been involved in increasing the viability 
of β cells by augmentation of WFS1 expression, gene expression analysis by microarray 
was performed. The findings revealed alterations in numerous genes, especially those 
involved in ER homeostasis and secretion (Tables 2.1 and 2.2). Interestingly, the most 
highly decreased gene was TXNIP. This gene is the most strongly induced gene in the β 
cell following exposure to hyperglycemic conditions 173. The protein product of this gene 
is involved in mediating ER stress-related cytokine induction in β cells and leads to β cell 
dysfunction. The fact that WFS1 augmentation decreased TXNIP strengthens the 
protective role of WFS1 signaling in both ER homeostasis and increasing cell viability. 
However, the microarray data also revealed some puzzling findings. Most notably, the 
expression of derlin-3 (Derl3) was strongly induced in cells expressing WFS1-WT, but 
decreased in WFS1-R611-expressing cells. Derlin-3 is induced by the UPR and is 
involved in ER-associated degradation. It is be possible that the considerably higher 
expression levels of WFS1-WT may be accountable for the increase in derlin-3 
expression. As a rule, the forced expression of genes of interest when researching the 
function of the ER and activation of the UPR must carry the caveat that high expression 
will alter ER homeostasis and this must always be considered when using this approach. 
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Sharpening the focus to survival and anti-apoptotic genes, the netrin signaling 
pathway was elucidated (Table 2.3). In cells with exogenous WFS1 expression, netrin-1 
was significantly increased and was further elevated in the protective WFS1-R611 allele. 
There was also some alteration in netrin receptors, as outlined in Table 2.3. Netrins are a 
group of secreted, laminin-related proteins originally discovered to be involved in 
chemotropic guidance of migrating cells and axons during neural development 175. 
Outside of the central nervous system, netrins and their receptors are expressed during 
development, contributing to the morphogenetic process and organization of multiple 
tissues. The netrin family of proteins is involved in directing cell migration and mediating 
cellular adhesion in the developing lung 176. In mammary gland development, netrin is 
involved in terminal bud development 177. Netrin signaling contributes to the formation of 
the semicircular canals in the inner ear 178. In addition, netrins have been implicated in 
vasculogenesis, development of the lymphatic system, muscle development, and 
chemorepellence of leukocyte 179-183. 
During the development of the pancreas, netrins and their receptors are also 
expressed 165, 166. Yebra et al (2003) demonstrated the role of Netrin-1 as an adhesive and 
migratory signal for CK19+/PDX1+ putative pancreatic progenitors. In a separate study, 
netrin-1 was also found to contribute to pancreatic morphogenesis 166. However, these 
authors also identified the upregulation of netrin-1 expression in β cells in islets distal to 
a pancreatic duct ligation injury model, suggesting that netrin-1 secretion from islets may 
stimulate the migration of precursor progenitor cells during budding islet morphogenesis. 
The results from the current DNA microarray experiment showed increased netrin-1 
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expression in both allelic variants of WFS1, which was significantly higher in the 
“protective” R611 allele. This suggests that the augmentation of WFS1 expression in β 
cells may signal the upregulation of netrin-1 expression, leading to an increase in netrin-1 
concentration in the local environment. Since netrin-1 has been shown to recruit islet 
progenitor cells, it is tempting to speculate that WFS1-induced increase in netrin-1 
expression would recruit more progenitor cells 165. With regards to the protective effect of 
the R611 allele against T2DM development, it is possible that increased netrin-1 
expression and release would facilitate enhanced recruitment of progenitor cells and 
maintenance of β cell mass, precluding T2DM progression. 
 In addition to the involvement of netrin-1 in axonal guidance and branching 
morphogenesis, netrin-1 has been shown to directly prevent β cell apoptosis 167. Yang et 
al (2011) administered netrin-1 to MIN6 insulinoma cells treated under hyperglycemic 
conditions. Their findings revealed a significantly lower apoptotic index for those cells 
treated with netrin-1. Notably, netrin-1 did not have any effect on β cell proliferation or 
insulin release. Therefore, the observation of increased netrin-1 signaling in cells 
expressing WFS1 in the current gene expression analysis may further suggest that netrin-
1 may directly sustain β cell viability as a paracrine or autocrine signal. The anti-
apoptotic role of netrin-1 and the fact that the expression of netrin-1 is significantly 
enhanced by the protective WFS1-R611 allele further supports the involvement of this 
allele in protection against T2DM by maintaining β cell mass. 
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FUTURE DIRECTIONS 
The results from this chapter highlight the importance of WFS1 in the function 
and survival of pancreatic β cells. However, there are a number of experiments needed to 
complete this body of work. Netrin-1 signaling was identified from the DNA microarray 
and its induction was validated by qPCR. An initial attempt for to demonstrate the 
increased expression of netrin-1 in cells with elevated WFS1 expression by 
immunoblotting was not fruitful. It is possible that netrin-1, a secretory protein, is purely 
released such that its detection method must be through ELISA rather than 
immunoblotting. Netrins function by interacting with cell surface-bound receptors. In this 
study, there was considerable alteration in the expression of distinct netrin receptors in 
the WFS1-expressing cell lines. This expression profile should be confirmed and 
explored in more detail to ascertain which receptors are involved in maintaining β cell 
viability following ligation by netrin-1.  
Augmentation of WFS1 expression in INS-1 832/13 cells suggested increased 
insulin content and secretion, and protection from ER stress. In view of these findings, it 
may be of interest to generate a transgenic mouse that overexpresses the WFS1 gene in 
the β cell to further examine the mechanisms by which β cell secretion and viability are 
enhanced by WFS1. 
In the current research, the expression level of each WFS1 allele in INS-1 832/13 
cells was not equal. To overcome this, it may be beneficial to introduce WFS1 into the 
cells by an adenoviral-mediated system instead. The advantage of this system is that 
identical titers of adenovirus-bearing WFS1 alleles could be used to ensure that the 
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expression level of each WFS1 allele would be alike. This would obviate any confusion 
over expression levels and eliminate the use of doxycycline from the experiments. 
Alternatively, zinc-finger nuclease (ZFN) technology could be utilized to insert a single 
or multiple copies of the WFS1 allelic variants into the AAVS1 site. This would ensure 
identical gene number and remove the possibility of differences in expression of the 
alleles in the different cell lines. A follow-on experiment prior to the arrival of transgenic 
animals would be the augmentation of WFS1 expression in mouse or cadaver-derived 
human islets. The adenovirus-mediated delivery system or ZFN-mediated insertion would 
again be optimal approaches for exogenous islets. In preparation for these experiments, 
both of the WFS1 alleles have been cloned into adenoviral constructs and are ready to be 
generated. Adenoviral constructs containing netrin-1 may also be developed to examine 
netrin-1’s role in β cell protection. 
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CHAPTER III 
MICRORNA-29B EXPRESSION IS INDUCED AS A  
COMPENSATORY SURVIVAL MECHANISM IN WFS1-/- ISLETS 
 
SUMMARY 
 In Wolfram syndrome, unregulated ER stress and UPR hyperactivation leads to 
dysfunction and death of β cells and optical neurons, which present clinically as the 
hallmark Wolfram disease symptoms of juvenile-onset diabetes mellitus and progressive 
optical atrophy, respectively. The deficiency of WFS1 protein also contributes to the 
progressive demise of hypothalamic, otic, and cerebellar neurons, leading to the 
development of diabetes insipidus, sensorineural deafness and ataxia, respectively.  
 To elucidate the molecular pathways to dysfunction in Wolfram syndrome, 
researchers use various cell culture-based and animal models of the disease. Mouse 
models of the disease include the whole-body and β cell-specific Wfs1 deletion models 
130, 184. While these animals portray progressive glucose intolerance, they do not develop 
frank diabetes due to survival of sufficient residual β cells to maintain blood glucose at 
normal levels. The remaining β cell mass are under chronic ER stress due to both lack of 
functional WFS1 protein and the increased demand for insulin production. 
The goal of this chapter was to identify microRNA that may be involved in the 
maintenance of β cell viability in which WFS1 is deficient. Microarray data revealed the 
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induction of the mir-29 family in Wfs1-/- islets. The expression levels of ER stress 
transducers IRE1, PERK, and ATF6, and UPR genes CHOP and BiP were decreased 
following treatment of thapsigargin-treated cells with a miR-29b mimic. The ER stress-
related pro-apoptotic genes PUMA and Bim-EL were significantly reduced by treatment 
with a miR-29b mimic. Collectively, these data suggest that in the absence of WFS1 
protein, β cells induce the expression of members of the miR-29 family as a 
compensatory survival mechanism to regulate the chronic UPR activation and ER stress 
in the cells in an effort to sustain β cell mass. 
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INTRODUCTION 
 The function of the endoplasmic reticulum varies slightly on a cell-specific or 
tissue-type manner. In most cells, the role of the ER is in the productive folding of 
proteins. ER homeostasis fluctuates dynamically in response to changes in protein client 
load in the ER, extracellular cues and intracellular metabolic conditions. Circumstances 
that perturb ER function and cause an imbalance in the ER‟s protein folding capacity 
precipitate ER stress, from which a specific response, the UPR, is activated. The overall 
goal of UPR activation is the palliation of ER stress conditions and restoration of ER 
homeostasis.  
Components of the UPR include the three ER transmembrane transducers, ATF6, 
IRE1, and PERK, and a variety of transcription factors and induced genes. The adaptive 
signaling of the UPR has three key mechanisms to achieve ER homeostasis: increase the 
protein-folding capacity of the ER, translational attenuation, and enhancement of 
proteasomal degradation. The majority of these mechanisms are achieved by direct 
protein-protein interaction.  
However, very little is known about the flux in miRNA expression that occurs 
subsequent to the induction of ER stress and the UPR. MicroRNAs are a unique class of 
small non-coding RNA genes that generate 18-25 nucleotide (nt) RNA molecules. 
Transcription of miRNA genes is performed by RNA polymerase II to yield pri-miRNAs, 
which subsequently undergo „cropping‟, mediated by Drosha and DiGeorge syndrome 
critical region gene 8 (DGCR8), to form the 65 nt pre-miRNA. Upon nuclear export, the 
RNase III Dicer „dices‟ the pre-miRNA to generate 22 nt miRNA duplexes, which is next 
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assembled into the RNA-induced silencing complex (RISC), where mRNA are 
selectively targeted by the miRNA and destroyed 185. 
The rapidly-expanding field of miRNA is being heavily mined to identify new 
targets and there have been a number of recent advancements in miRNAs linked to ER 
stress. The UPR-induced transcription factor CHOP increases the expression of Odz4, a 
member of the teneurin family of developmental regulators essential for neural 
development. Within the first intron of Odz4 resides the gene encoding miR-708; CHOP 
co-regulates their transcription 155. In an elegantly integrative manner, miR-708 functions 
as a unique component of the UPR whereby it decreases the protein load on the ER by 
targeting rhodopsin mRNA for destruction.  
In a similar manner to that of miR-708, PERK-induced expression of miR-30c-2* 
directly targets the 3‟-untranslated region (UTR) of XBP-1 mRNA, preventing 
hyperactivation of the UPR 158. However, the UPR-specific transcription factor XBP-1 
also promotes transcription of the miR-346 gene. miR- 346 targets the mRNA of the 
human antigen peptide transporter 1 (TAP1), precluding entry of client proteins into the 
ER and reducing ER stress 156. Using human hepatocellular carcinoma cells, Dai et al 
(2010) showed that miR-221/222 is decreased by ER stress. Suppression of miR-221/22 
mediated a protective role against ER stress-induced apoptosis 186.  
Various forms of cells stress which may impinge on the function of the ER have 
been linked to miRNAs. Within the pancreatic β cell, where the ER is a fundamental 
organelle for cellular function, the expression of miR-375 may impact ER function as it is 
involved in negatively regulating glucose-stimulated insulin secretion by controlling the 
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level of myotrophin 150. Another cell type with an extensive and expansive ER network 
that is essential for cell function is the antibody-secreting plasma cell. In this cell, miR-
155 regulates the production of isotype-switched, high affinity antibodies 187. Hypoxia is 
another cellular stress that impacts ER homeostasis and initiates the UPR; the hypoxia-
induced miR-120 has been shown to regulate normoxic gene expression involved in 
tumor initiation 188. 
There is slowly accumulating evidence that miRNAs are involved in both ER 
stress induction and regulation. The WFS1-/- mouse model of Wolfram syndrome-related 
ER dysfunction and diabetes mellitus is another paradigm to identify miRNA involved in 
ER stress-mediated dysfunction or diabetes. Following that lead, the results of this 
chapter reveal the alteration of various miRNA families in the WFS1-/- islets. In 
particular, the enhanced expression of the miR-29 family was further explored and shown 
to be involved in the diminution of all three UPR transducers and other ER stress 
markers. Pro-apoptotic genes and activated caspase-3 were also decreased by a miR-29b, 
a member of the miR-29 family. These data contribute to the notion that ER stress-
activated miRNAs are active members of the UPR and are involved in the restoration of 
ER homeostasis. By this mechanism, these miRNA promote cell survival. 
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MATERIALS AND METHODS 
Animals 
  cell-specific WFS1-/- mice were generously provided by Dr. M. Alan Permutt 
(Washington University, St. Louis, MO) and bred as an heterozygote mixed colony at 
UMass Medical School, Worcester, MA. Confirmation of WFS1 absence was performed 
by PCR analysis of genomic DNA for Cre recombinase and WFS1 using the methods 
published by Riggs et al (2005). All animals were maintained in a viral and pathogen-free 
(VPF) environment with ad libitum access to food and water, in accordance with the 
guidelines of the University of Massachusetts Medical School Institutional Animal Care 
and Use Committee (IACUC) and the Guide for the Care and Use of Laboratory Animals 
(Institute of Laboratory Animal Resources, National Research Council, National 
Academy of Sciences, 1996). 
 
Intraperitoneal Glucose Tolerance Test (IPGTT) 
The blood glucose and weights of 24 week-old WRC mice and litter-mate 
controls were obtained and the animals were fasted overnight. The next day, the mice 
were again weighed and baseline blood glucose readings were obtained. A 20% glucose 
solution was administered at 2g/kg pre-fast body weight by intraperitoneal injection. 
Glucose readings were obtained at 15, 30, 60, 90, and 120 min post-administration using 
a handheld glucometer (Lifescan Inc., Milpitas, CA). 
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Islet Isolation and Culture 
Islet donor mice were anesthetized with intraperitoneal injection of sodium 
pentobarbital and maintained anesthetized via inhalational halothane. Alternatively, 
donor mice were rendered dead via carbon dioxide inhalation and cervical dislocation. 
Upon exposure of the abdominal cavity, the pancreas was ballooned by pancreatic duct 
injection of 5mls of 1.0 mg/ml collagenase P (Roche) solution in HBSS. Ballooned 
mouse pancreata were extracted, washed with warm RPMI and incubated at 37°C for 25 
minutes with mild agitation to enable complete collagenase digestion of the pancreatic 
extracellular tissue. Digestion was stopped by addition of ice-cold RPMI containing 1% 
horse serum (1% RPMI). Subsequently, digested pancreata were allowed to settle to the 
bottom of the tube and the supernatant was decanted. The tissues were then washed with 
ice-cold 1% RPMI. Using a 14 gauge needle on a 10cc syringe, the tissues were 
mechanically disrupted, followed by centrifugation at 1000rpm for 10 seconds and 
decanting of the supernatant. The mechanical disruption and centrifugation steps were 
repeated once more. The tissues were next resuspended in 1% RPMI, strained through a 
metal sieve, which were then rinsed with 1% RPMI. The sieved tissue homogenate was 
centrifuged at 1200 rpm for 10 seconds and the supernatants were vacuum-aspirated. The 
pancreatic homogenate was centrifuged again and as much of the supernatant as possible 
was removed by vacuum-aspiration. Pellets were resuspended in 10ml of Histopaque 
1077 and gently homogenized by tapping; the homogenate was then overlaid with 10ml 
of 1% RPMI. This gradient was centrifuged at 1800 rpm for 20 min at 20°C without 
brake. Islets were collected from the interface of the Histopaque and RPMI by glass 
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pipette and placed into a tube with RPMI containing 5% horse serum (5% RPMI). Islets 
were washed twice with 50ml of 5% RPMI by centrifugation at 1200 rpm for 10 seconds 
at room temperature. Islets were placed in a 100mm petri dish in 10mls of 5% RPMI 
under a dissecting microscope and handpicked for counting. Counted islets were again 
washed in 15ml RPMI and centrifuged at 1200rpm for 30seconds. The islets were then 
stored in microfuge tubes in 250μl RPMI prior to use. Islet isolation was expertly 
performed by Linda Leehy or Elaine Norowski in the Greiner laboratory and Mariko 
Hara in the Urano laboratory (UMass Medical School, Worcester, MA). Mouse islets 
were cultured in RPMI medium containing 10% fetal bovine serum, 1% 
Penicillin/Streptomycin, 1% sodium pyruvate, and 0.1% β-mercaptoethanol allowing for 
recovery by overnight incubation. 
 
Cell Culture 
The rat insulinoma cells, INS-1 832/13, were cultured in RPMI 1640 medium 
containing 10% Tetracycline-free FBS, 1% Pen/Strep, 0.1% -mercaptoethanol, and 1% 
sodium pyruvate. The mouse insulinoma cell line, MIN6, were maintained in DMEM 
containing 15% FBS, 1% sodium pyruvate, and 1% Pen/Strep. MIN6 cells harboring 
doxycycline-inducible short-hairpin RNA (shRNA) targeting WFS1 (MIN6-shWFS1) 
and non-specific control scrambled (MIN6-shSCR) had been previously established by 
Shinsuke Ishigaki. 
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miRNA microarray 
Total RNA was isolated using a miRNeasy mini kit (Qiagen, Valencia, CA). 
Microarray analysis was performed on triplicate RNA samples of islets isolated from 24 
week-old WFS1-/- islets or age-matched littermate control Cre+/+, Wfs1+/+ mice using the 
miRBase sequence database version 17 from LC Sciences (LC Sciences, Texas).  
 
Real-Time Qualitative Polymerase Chain Reaction (qPCR) 
Total RNA was isolated using miRNeasy Mini kit (Qiagen, Valencia, CA) and 
cDNA was generated by reverse transcription of 1µg of template RNA using the miScript 
Reverse transcription kit. Triplicate qPCR samples were analyzed using the iQ5 system 
(BioRad, Hercules, CA) with the miRNA-specific PCR program: 95°C for 15min, 35-40 
cycles of 94°C for 15sec denaturation steps, 55°C for 30sec annealing step, and 70°C for 
30sec extension step. The relative expression of each transcript was determined by a 
standard curve of cycle thresholds for serial dilutions of cDNA and normalized to the 
expression of actin. The miScript SYBR Green PCR kit (Qiagen) and the following 
miScript Primer Assays were used: Mm_miR-1224_1, Mm_miR-1940_1, Mm_miR-
494_1, mmu-miR-5112 custom primer, Mm_miR-29a_1, Mm_miR-29b_1, Mm_miR-
29c_1, Rn_miR-29a_2, Rn_miR-29b_1, Rn_miR-29c_1 (Qiagen) were used for real-time 
quantitative PCR. 
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miRNA mimic transfection 
 INS-1 cells were harvested by trypsinization and stored on ice until needed. 
Transfection of miRNA mimic was performed using HiPerFect transfection reagent and 
the reverse transfection protocol (Qiagen). Briefly, 37.5ng of miRNA mimic was spotted 
onto each well of a 24 well-plate in 100µL of OptiMem medium (Invitrogen). To this, 
3µL of HiPerFect transfection reagent was added and complexes were allowed to form 
for 5-10 min at room temperature. INS-1 cells at a density of 40,000-160,000 in 500µL 
culture medium were added to each well. Specific miRNA mimic included Syn-rno-miR-
29b and the control was the AllStars Negative Control siRNA (Qiagen). 
 
Statistical Analysis 
Statistics on the data derived from the IPGTT and qPCR included one-way 
ANOVA with Bonferroni‟s post-test and was performed using the Graphpad Prism 
version 5.04 for Windows (Graphpad Software, La Jolla, CA. www.graphpad.com).  
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RESULTS 
Mice with a pancreatic β cell-conditional Wfs1 deficiency (WFS1-/-) display glucose 
intolerance 
 Previous studies on the whole-body and pancreatic β cell-specific WFS1-/- mouse 
models of Wolfram syndrome have demonstrated impaired glucose homeostasis, defined 
by the rapid elevation in blood glucose levels and indolent return to normoglycemia 
following intraperitoneal glucose challenge 130, 184. To validate their findings and 
demonstrate the phenotype in our WFS1-/- mouse colony, intraperitoneal glucose 
tolerance tests (IPGTT) were performed (Figure 3.1). At fifteen minutes post-
administration of the glucose load, there was a distinct, albeit not statistically significant, 
elevation in blood glucose in the WFS1-/- mice when compared to control mice. This 
trend continued to significance at the 30 minute time-point (p<0.001). While the blood 
glucose level of the control mice steadily returned to normal, the decline for the WFS1-/- 
mice was considerable slower, with the blood glucose readings for the WFS1-/- mice 
remaining significantly elevated throughout the remainder of the 2-hour experiment 
(Figure 1.3). These observations reconfirm those of previous investigators, indicating 
glucose intolerance in the WFS1-/- mice 130, 184. However, while the silhouette of the 
blood glucose for the WFS1-/- animals is shifted upwards and indicative of glucose 
intolerance, it does follow the same outline as the control mice, suggesting that there are 
residual β cells that are functional. Therefore, in the WFS1-/- mouse, there may be 
activation of specific pathways or genes that sustain β cell survival. 
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Figure 3.1: Intraperitoneal glucose tolerance test (IPGTT). Twenty-four week-old 
WRC (black triangles) and littermate control (grey circles) mice were challenged with 
2g/kg dose of glucose by intraperitoneal injection. Blood glucose readings were recorded 
over a 2-hour period. The pink bar represents the physiological range of normoglycemia 
in mice. 
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Wfs1-/- islets show diverse alterations in their microRNA expression profile 
 The pancreatic β cells in the islets of the WFS1-/- mouse are under chronic 
UPR activation status due to unresolved ER stress conditions. In accordance with this, all 
three pathways of the UPR are activated and the expression of downstream UPR marker 
genes is increased in WFS1-/- islets 124, 130. However, the involvement of specific miRNAs 
in WFS1 deficiency or chronic ER stress in β cells has not been explored. These small 
RNA molecules play important cellular roles in regulating a variety of biological 
processes including signal transduction, apoptosis, cell proliferation, developmental 
progression, and tumorigenesis 189-191. To date, there has only been one ER stress-related 
miRNA, miR-708, reported in the literature 155. Thus, it is possible that an alteration to 
the miRNA expression profile occurs in the WFS1-deficient β cells as a compensatory 
mechanism to palliate the unresolved ER stress and chronic UPR conditions. 
 To identify miRNAs that may be altered in WFS1 deficiency, isolated islets 
from WFS1-/- and control mice were processed for total RNA and sent for miRNA 
microarray analysis. The data from the microarray revealed that there is considerable 
fluctuation in the miRNA expression profile of WFS1-/- islets (Table 3.1). The most 
highly induced miRNAs in WFS1-/- islets included miR-1940 (fold change (FC) = 17.40), 
miR-5112 (FC = 8.39), miR-29b (FC = 4.42), miR-1224 (FC = 3.30), and miR-494 (FC = 
3.23) (Table 3.1). Of these miRNA, miR-1224 has recently been identified to be induced 
by lipopolysacchiride (LPS) and regulates NFκB expression 192. For those miRNA that 
were statistically significant and had high microarray signal scores, there seemed to be a 
trend towards increased expression of distinct miRNA families in the WFS1-deficient 
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islets. For instance, all three mature members of the miR-29 family, miR-29a (FC = 
1.59), miR-29b (FC = 4.42), and miR-29c (FC = 2.91), were strongly and statistically 
induced in the WFS1-deficient islets. The miR-29 family members display different 
regulation based on their subcellular distribution and tissue type; miR-29 members have 
been reported as being antifibrotic and pro- or anti-apoptotic 193. There were two 
members of the miR-154 family induced in the WFS1-/- islets: miR-494 (FC = 3.23) and 
miR-154 (FC = 1.57). miR-154 family members play a role in lung development 194. In 
addition, cardiac-specific overexpression of miR-494 led to the regulation of distinct 
proapoptic and antiapoptoic genes and protected against ischemia-reperfusion cardiac 
injury 195. Five members of the miR-8 family, miR-141 (FC = 1.93), miR-200a (FC = 
1.58), miR-200b (FC = 1.50), miR-200c (FC = 1.34), and miR-429 (FC = 1.27), were 
also induced in the WFS1-/- islets. Members of the miR-8 family have been reported to be 
involved in the regulation of Notch and Wnt signaling 196, 197. Interestingly, miR-200 is 
involved in the regulation of intracellular insulin signaling 198.  
 The downregulated miRNAs predominantly fell into one specific miRNA 
family – the miR-467 family. This family consists of the rapidly expanded rodent-
specific miRNA cluster located in the intron of the Sfmbt2 gene, a maternally-imprinted 
polycomb gene 199. Since these miRNA are rodent-specific, this could partially explain 
the survival of WFS1-/- β cells and incomplete recapitulation of Wolfram syndrome in 
animal models of the disease.  
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Up-regulated   
 
Down-regulated    
miRNA Log (G2/G1) Fold change p-value miRNA Log (G2/G1) Fold change p-value 
mmu-miR-1940 4.12 17.40 2.19E-04 mmu-miR-1895 -0.55 -1.46 1.20E-03 
mmu-miR-5112 3.05 8.29 7.60E-04 mmu-miR-214 -0.57 -1.48 6.35E-03 
mmu-miR-29b 2.14 4.42 7.26E-05 mmu-miR-1892 -0.66 -1.58 2.97E-04 
mmu-miR-1224 1.72 3.30 1.66E-04 mmu-miR-376b -0.74 -1.67 1.93E-03 
mmu-miR-494 1.69 3.23 5.68E-04 mmu-miR-3095-3p -0.77 -1.71 2.19E-03 
mmu-miR-29c 1.54 2.91 1.36E-03 mmu-miR-1187 -0.79 -1.73 9.03E-03 
mmu-miR-5105 1.35 2.55 3.47E-03 mmu-miR-483 -0.80 -1.74 7.98E-03 
mmu-miR-762 1.32 2.49 8.64E-03 mmu-miR-3099 -0.88 -1.84 5.21E-03 
mmu-miR-5117 1.29 2.45 5.96E-03 mmu-miR-15b -0.88 -1.84 1.42E-03 
mmu-miR-15a 1.15 2.22 1.89E-03 mmu-miR-574-5p -0.89 -1.85 1.31E-05 
mmu-miR-141 0.95 1.93 1.21E-03 mmu-miR-466h-3p -0.98 -1.98 7.74E-03 
mmu-miR-22 0.94 1.92 1.36E-03 mmu-miR-467f -1.02 -2.02 2.53E-03 
mmu-miR-690 0.90 1.86 2.53E-03 mmu-miR-5113 -1.02 -2.02 7.29E-03 
mmu-miR-129-1-3p 0.74 1.67 2.50E-03 mmu-miR-669a-3p -1.05 -2.07 8.66E-04 
mmu-miR-1839-5p 0.72 1.65 1.81E-03 mmu-miR-669c* -1.11 -2.15 1.41E-04 
mmu-miR-29a 0.67 1.59 6.34E-04 mmu-miR-467b* -1.17 -2.25 2.52E-03 
mmu-miR-200a 0.66 1.58 6.99E-03 mmu-miR-1897-5p -1.19 -2.27 1.40E-04 
mmu-miR-154 0.65 1.57 7.50E-03 mmu-miR-3082-5p -1.26 -2.39 5.95E-03 
mmu-miR-129-5p 0.61 1.53 7.42E-03 mmu-miR-669f-3p -1.27 -2.42 2.55E-04 
mmu-miR-379 0.60 1.52 9.86E-03 mmu-miR-466q -1.32 -2.49 3.30E-04 
mmu-miR-200b 0.58 1.50 5.40E-03 mmu-miR-466i-3p -1.32 -2.49 6.92E-03 
mmu-miR-705 0.55 1.46 1.06E-03 mmu-miR-3072* -1.34 -2.52 1.54E-03 
mmu-miR-1195 0.52 1.43 6.99E-03 mmu-miR-467d* -1.39 -2.62 1.40E-03 
mmu-miR-3963 0.48 1.39 1.32E-03 mmu-miR-1966 -1.43 -2.69 2.49E-03 
mmu-miR-185 0.48 1.39 3.75E-03 mmu-miR-466g -1.48 -2.78 5.39E-03 
mmu-miR-383 0.43 1.34 9.72E-03 mmu-miR-669e* -1.49 -2.81 3.35E-03 
mmu-miR-200c 0.42 1.34 1.68E-03 mmu-miR-669n -1.51 -2.84 7.72E-04 
mmu-miR-183 0.42 1.34 4.11E-03 mmu-miR-669c -1.52 -2.87 7.86E-04 
mmu-miR-425 0.37 1.30 6.65E-03 mmu-miR-574-3p -1.59 -3.01 1.21E-03 
mmu-miR-429 0.34 1.27 6.39E-03 mmu-miR-466m-3p -1.69 -3.22 5.02E-04 
 
  
 
mmu-miR-32* -1.73 -3.32 4.53E-03 
 
  
 
mmu-miR-467a* -1.75 -3.37 3.01E-04 
 
  
 
mmu-miR-150 -1.87 -3.65 3.49E-03 
 
  
 
mmu-miR-669f-5p -1.90 -3.72 1.61E-05 
 
  
 
mmu-miR-466m-5p -1.96 -3.89 4.36E-03 
 
  
 
mmu-miR-467c* -2.00 -4.01 9.65E-04 
 
  
 
mmu-miR-669a-3-3p -2.01 -4.02 7.45E-04 
 
  
 
mmu-miR-467e* -2.12 -4.34 2.28E-03 
 
  
 
mmu-miR-467g -2.14 -4.42 1.59E-04 
 
  
 
mmu-miR-3097-5p -2.25 -4.77 3.59E-04 
 
  
 
mmu-miR-568 -3.03 -8.17 1.01E-04 
 
Table 3.1: List of miRNA with altered 
expression from WFS1-/- islets compared 
to control islets. Statistically significant 
miRNA increased or decreased in expression 
in the WFS1-/- islets. The miR-29 (light 
gray), miR-154 (light blue), miR-8 (light 
green), and miR-467 (light pink) miRNA 
families are highlighted. 
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Wfs1-/- islets have increased expression of the miR-29 family members 
 The miRNA microarray lead to the identification of numerous miRNA families 
that were increased or decreased in the chronic ER stress conditions of the WFS1-
deficient environment of the WFS1-/- islets. All three members of the miR-29 family, 
miR-29a, miR-29b, and miR-29c, were substantially upregulated in the WFS1-/- islets 
compared with littermate control islets. Thus, this miRNA family was chosen for further 
analysis.  
To confirm the induction of this miRNA family, total RNA preparations from 
WFS1-/- and control mice were subjected to miRNA qPCR using specific primer assays 
for each miRNA family member. The results confirmed the miRNA microarray data 
where all three members of the miR-29 family, miR-29a, miR-29b, and miR-29c were 
elevated in the WFS1-/- islets (Figure 3.2) 
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Figure 3.2: Confirmation of increased expression of miR-29 family members in 
WFS1-/- islets. Total RNA from WFS1-/- and control (WFS1+/+) islets were probed for 
members of the miR-29 family (miR-29a, miR-29b, and miR-29c). Data are expressed as 
relative expression over RNU6 control. 
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Introduction of miR-29b mimic into INS-1 cells decreases the expression of UPR 
markers and ER stress transducers 
 There are numerous physiological and pathological conditions that lead to the 
induction of ER stress in pancreatic β cells. In research, ER stress can also be triggered 
by the use of chemical agents such as the SERCA inhibitor, thapsigargin (TG). Once ER 
stress has been initiated, the three protein transducers (ATF6, IRE1, and PERK) on the 
ER membrane recognize the alteration of ER homeostasis and initiate the UPR. The 
downstream signaling events of the UPR lead to the increase in expression of specific 
genes that contain the unfolded protein response element (UPRE) or ER stress element 
(ERSE) in their promoter; some of these genes include BiP and CHOP. To determine the 
possible involvement of mir-29 family members in regulation of ER stress in β cell, ER 
stress was induced with TG in the presence or absence of a synthetic miR-29b mimic. All 
members of the miR-29 family have the same mRNA targets, but an analog of mir-29b 
was specifically chosen as the prototypical miR-29 family member because its expression 
was highest in the in the microarray data. INS-1 cells treated with TG lead to a 4-fold 
increase in CHOP expression and 3.5-fold increase in BiP expression (Figure 3.3a, b). 
Pretreatment with the miR-29b mimic prevented the elevation of CHOP and BiP 
expression in TG-treated cohorts. There was a strong statistically significant reduction in 
CHOP expression in “TG+/miR-29b mimic” group to approximately 50% of “TG+/ 
RNAi control”, while there was a significant 20% reduction in BiP expression in the 
same cohort (Figure 3.3 a, b).  
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The three transducers that sense ER stress and initiate the UPR are ATF6, IRE1, 
and PERK. INS-1 cells treated with “TG+/control RNAi” displayed increased expression 
of all three transducers (Figure 3.3c, d, e). Similar to the previous finding of decreased 
CHOP and BiP expression, miR-29b mimic pretreatment significantly decreased the 
expression level of all three transducers (Figure 3.3c, d, e). Interestingly, miR-29b had no 
effect on the expression of insulin 2 (Figure 3.3f). 
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Figure 3.3: miR-29b decreases expression of ER stress markers and UPR 
transducers. Treatment of INS-1 cells with thapsigargin induces ER stress (a-f); miR-
29b co-treatment prevents TG-induced increase in ER stress markers (a) BiP and (b) 
CHOP and decreases the expression of the UPR transducers (c) ATF6, (d) IRE1, and (e) 
PERK. (f) There is no effect of miR-29b on Insulin2 expression. 
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Exogenous administration of miR-29b decreases the expression of the UPR-related 
apoptotic genes PUMA and Bim-EL 
 Activation of the UPR following ER stress is an initial attempt by the cell to 
restore ER homeostasis. This is achieved by limiting the entry of proteins into the ER and 
increasing the folding capacity of the ER with supplementary chaperones. However, with 
chronic, irresolvable ER stress, the UPR switches to promote apoptotic signaling 200. 
Some of the downstream pro-apoptotic targets of the UPR include the BH3-only family 
members, such as p53-upregulated modulator of apoptosis (PUMA) and Bim-EL. In a 
recent publication, mir-29b was shown to be specifically target PUMA and Bim-EL 
mRNA for degradation, precluding apoptosis in maturing neurons.  
 To ascertain whether mir-29b had any effect on BH3-only family members in β 
cells, INS-1 cells were treated with the ER stress inducer TG in the presence or absence 
of mir-29b mimic. PUMA and Bim-EL were assessed by qPCR. Treatment with TG 
caused a substantial increase in the expression of both PUMA and Bim-EL. However, co-
treatment with the miR-29b mimic decreased the expression level of both genes (Figure 
3.4). This result confirms the role of miR-29b in regulating the BH3-only family 
members PUMA and Bim-EL and postulates a role for miR-29 family members in 
controlling apoptosis in the WFS1-/- islet. 
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Figure 3.4: miR-29b decreases the expression of UPR-related apoptotic genes. TG-
induced increase in PUMA and Bim-EL expression was blunted in the presence of the 
miR-29b mimic. 
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ER stress-mediated caspase-3 cleavage is reduced in the presence of the miR-29b 
mimic 
 The terminal caspase in the apoptotic pathways is caspase-3. This 32kDa protein 
is activated by splitting it into 12 and 17kDa cleavage products, which form the active 
caspase-3 forms. To determine whether mir-29b could limit apoptosis through the 
moderation of caspase-3 activation, protein lysates of INS-1 cells treated with TG and 
either the miR-29b mimic or control siRNA, were examined by immunoblotting. As 
depicted in Figure 3.5, miR-29b mimic was capable of decreasing the activation of 
caspase-3. This observation further strengthens the role of the increased expression of the 
miR-29 family members in the WFS1-/- islets as a compensatory mechanism to sustain β 
cell survival. 
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Figure 3.5: miR-29b prevents the activation of caspase-3 in TG-treated INS-1 cells. 
ER stress induction by TG leads to the cleavage of caspase-3 as apoptosis ensues. The 
presence of the miR-29b mimic decreases TG-induced caspase-3 activation.  
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DISCUSSION 
The increase in ER stress markers and activation of UPR transducers has 
convincingly been shown in β cells with deficiency of WFS1 protein 124, 128, 130. In this 
chapter, the alteration in the miRNA expression profile in WFS-deficient islets was 
examined. The results propose a novel mechanism for sustaining β cell mass despite 
chronic ER stress conditions due to WFS1 deficiency. Increased expression of the miR-
29 family in WFS1-/- islets and its involvement in regulating ER stress transducers and 
ER stress-related pro-apoptotic genes supports the conceptual role of miRNA as associate 
UPR members. In this study, miR-29 family members act as counter-regulatory UPR 
components that diminish the activation status of the UPR and limit apoptosis.  
The burgeoning influence of miRNA on various biological processes, including 
the outcome and regulation of the UPR, is being explored with great enthusiasm. In the 
past few years, a number of ER stress-related miRNAs have been reported in the 
literature. These include the XBP-1-driven miR-346, PERK-induced miR-30c-2-3p, 
ATF6-mediated suppression of miR-455, and the CHOP-transcribed miR-708 155-158. In 
this chapter, this list is expanded to include the members of the miR-29 family. 
There is considerable information on the miR-29 family. A large body of work 
involves the role of miR-29 members in controlling the fibrotic response in 
cardiomyocytes, lung tissue, liver, and kidney 201-204. Other research areas that have 
reported the involvement of miR-29 include cancer, myoblast differentiation, 
osteoblastogenesis and immunology 205-208. The association of miR-29 with various 
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cancers is complex: miR-29 is elevated in some cancers where it functions as an 
oncogene 209, 210. However, others have observed anti-apoptotic functions of miR-29 211, 
212. In regards to the pancreatic β cell, miR-29a and miR-29b have been shown to be 
involved in controlling the pancreatic β cell-specific silencing of monocarboxylate 
transporter 1 (Mct1) 213. Examination of the diabetic Goto-Kakizaki rat revealed 
upregulation of all three members of the miR-29 family in muscle, fat, and liver 214. In 
that study, elevated miR-29 was associated with insulin resistance in adipocytes. It seems 
that miR-29 family has a number of roles depending on the tissue location. 
In this research, the introduction of a miR-29b mimic into INS-1 832/13 cells 
prevented the increase in UPR transducer expression by the ER stress agent, thapsigargin 
(TG). It is interesting that all three members of the UPR transducers were decreased, 
especially given the fact that there is no readily identifiable target recognition site for the 
miR-29 members in any of the three transducers. It seems that miR-29 may play an 
indirect role in the regulation of the transducers and it would be worthwhile to determine 
the expression of their transcription factors and whether miR-29 family members can 
regulate their expression. Exogenous miR-29b mimic also prevented the expected TG-
induced increase in ER stress markers CHOP and BiP. This may be due to the regulation 
of the aforementioned UPR transducers. 
The involvement of miR-29 family members in controlling the expression of 
BH3-only proapoptotic genes has recently been published 215. Kole et al (2011) 
demonstrated that during the maturation process of neurons, the expression of miR-29b is 
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dramatically induced and functions as a novel inhibitor of neuronal apoptosis. The 
authors proceeded to show that miR-29b specifically targets the mRNA of the BH3-only 
proteins PUMA, Bim, Hrk, and Bmf. In the current research reported in this chapter, 
miR-29 members were found to be induced in WFS1-/- islets, which are under chronic ER 
stress conditions. PUMA, Noxa, and Bim-EL are ER stress-induced BH3-family 
members that promote apoptosis 216, 217. Therefore, since miR-29b has been shown to 
regulate BH3-only member expression previously, the role of miR-29 in regulating 
chronic ER stress-induced BH3-only members in WFS1-/- islets was determined. It was 
found that a miR-29b mimic decreased the expression TG-induced BH3-only members. 
Thus, it is plausible to suggest that the chronic ER stress condition of the WFS1-deficient 
islets signals the induction of miR-29 family members as a counter-regulatory 
mechanism to prevent UPR hyperactivation and prevent apoptosis.  
The recent reports of the involvement of various miRNA in regulating the UPR 
and ER stress are intriguing. In the chronic absence of WFS1 in WFS1-/- islets, 
unresolved ER stress and UPR hyperactivation occurs. Of the ER stress-related miRNA 
found in the other studies, only miR-346 expression was altered in this study. However, 
the expression of miR-346 was decreased in this research and was increased by XBP-1 in 
the previous study. A possible reason for this discrepancy may be cell-dependent 
differential expression of miRNA. Ultimately, the data herein report the elevated 
expression of the miR-29 family in WFS1-/- cells and that miR-29b, a prototypical family 
member, decreases UPR transducers and ER stress markers, and precludes activation of 
105 
 
caspase-3. These data strengthen the idea of miRNA as novel regulators of the UPR and 
provide a mechanism by β cells maintain viability in the face of WFS1 deficiency. 
 
FUTURE DIRECTIONS 
In this chapter, the expression of the miR-29 family was observed to be 
upregulated in WFS1-/- islets as compared to control islets. miR-29 decreased the 
expression of ER stress markers, UPR transducers, and ER stress-related pro-apoptotic 
genes, and decreased caspase-3 cleavage in insulinoma cells. So far, examination of miR-
29 protection has focused on changes in mRNA expression. To follow up, the expression 
level of UPR transducers and ER stress markers should be assessed by immunoblot 
analysis. There are no miR-29 recognition sites in the 3‟ UTR regions of the UPR 
transducers. To extend the findings further, the mechanism by which miR-29 members 
indirectly regulate UPR transducer expression should be elucidated and may revela novel 
targets for manipulation of the UPR as a therapeutic approach for ER stress-related 
diseases. Additionally, the protective role of miR-29 family members should be extended 
to include human islets. To do so, adenoviral constructs expressing miR-29b could be 
used to deliver and transiently express the miRNA in donor human islets followed by 
challenge with ER stress-inducing agents and assessment of viability. 
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Figure 3.6: Potential role of miR-29b as an ER stress regulating molecule. This 
chapter reveals the increase in miR-29 family members as an adaptive alteration to 
deficiency of WFS1 and provides a route to sustain β cell viability despite chronic ER 
stress and UPR activation. miR-29 members regulate the expression of UPR transducers 
and UPR-related apoptotic factors. 
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CHAPTER IV 
DISCUSSION AND PERSPECTIVES 
 
 Diabetes mellitus is an umbrella term that encompasses a number of diverse 
diseases with varying pathogenesis that all involve the state of hyperglycemia, or 
increased blood glucose levels. On the basis of their pathogenesis, the diabetic subtypes 
are established: these include the autoimmune-driven T1DM, genetically-derived 
Wolfram syndrome, MODYs and MIDY, and the insulin-resistant, metabolic syndrome-
originating T2DM. Of the forms of diabetes, T2DM has the highest incidence and is a 
highly prevalent, chronic, global disease that is rapidly expanding, with a predicted 
number of diabetic individuals worldwide of over 366 million by the year 2030 21. 
Diabetes-related complications include cardiovascular disease, neuropathy, nephropathy, 
retinopathy, and decreased immunity and are directly related to the chronic elevation of 
blood glucose and the generation of toxic advanced glycation end-products.  
 Current therapies for T2DM comprise pharmaceuticals that address different 
aspects of the disease: the biguanides (e.g. metformin) and thiazolidinediones (e.g. 
pioglitazone) are used to reduce insulin resistance; the sulfonylurea drugs (e.g. glyburide) 
and meglitinides (e.g. repaglinide) act directly on the pancreatic β cell as insulin 
secretagogues; and the alpha-glucosidase inhibitors (e.g. acarbose) decrease 
gastrointestinal carbohydrate metabolism, limiting glucose absorption. The only 
108 
 
medicinal approach that has a protective effect on β cells are the incretin-based therapies: 
the GLP-1 agonists (e.g. exanatide) and analogues (e.g. liraglutide). The DPP4 inhibitors 
(e.g. sitagliptin) indirectly increase GLP-1 which protects β cells. Thus, it’s apparent that 
the majorities of current anti-diabetic medications act in a palliative manner to control 
hyperglycemia, but do not stop the evolution of the disease. Often, diabetic patients have 
to increase the dosage of their medications and add supplementary medications to their 
anti-diabetic regimen as the disease progresses. Therefore, there is a need to develop 
therapeutic modalities that limit the progression or reverse the course of diabetes. One 
approach to achieve this goal is by investigating the pathogenesis of the different diabetes 
subtypes in order to identify the molecular pathways that promote survival and 
maintenance of β cells.  
 Accumulating evidence proposes a link between ER stress and pancreatic β cell 
function, hypothesizing that alterations to ER homeostasis which lead to ER stress could 
result in β cell dysfunction 8, 104. Extracellular conditions and genetic diseases that cause 
ER stress have been implicated in the pathogenesis of T1DM and T2DM 94-102. One 
disease that has been linked to both ER stress and diabetes mellitus is Wolfram 
syndrome. In this condition, mutations in the Wfs1 gene on chromosome 4 cause 
truncations such that shortened, non-functional, misfolded, and rapidly-degraded forms of 
WFS1 protein are formed 128. WFS1 protein normally resides on the membrane of the ER 
or secretory granules 128, 131. On the ER surface, WFS1 responds to ER stress and UPR 
activation by decreasing the amount of the UPR transducer ATF6 by directing it towards 
the proteasome for degradation 129. In addition, WFS1 co-regulates the activity of the 
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anti-apoptotic transcription factor AATF 159. Thus, WFS1 is protective in the β cell by 
preventing UPR hyperactivation and apoptotic signaling. The presence of WFS1 on 
secretory granules provides an additional advantage whereby WFS1 is involved in 
maintaining secretory granule acidity necessary for insulin maturation and secretion 131. 
More recently, Wfs1 gene was included as a T2DM susceptibility gene and a number of 
SNPs in Wfs1 have been associated with increased risk of T2DM development 138-143, 160-
164.  
In the development of diabetes, environmental and genetic factors are strong 
contributory factors. The concordance rate of T1DM between of monozygotic twin is 
approximately 40%, while that of T2DM is close to 80%, significantly higher than 
T1DM. This suggests that genetic factors are extremely important for diabetogenesis, 
especially for T2DM. Therefore, in this thesis, since the Wfs1 gene has been associated 
with T2DM development, one of the SNPs of Wfs1, H611R, was chosen for further study. 
The goal of this project was to elucidate a possible mechanism by which the arginine (R) 
allele at amino acid residue 611 was ‘protective’ against T2DM development. 
Comparative gene expression of the alleles identified genes that were similarly and 
differentially regulated by the two alleles and uncovered a specific signaling pathway 
strongly activated by the R611 allele that promotes protection against diabetogenesis.  
In Chapter II, the alleles at SNP rs734312 (H611R) of WFS1 were compared by 
inducing their expression in an insulinoma cell line. It was found that augmentation of the 
expression of either allele led to an increase in both cellular insulin content and insulin 
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secretion, which is supported by the previous finding of the subcellular location of WFS1 
protein on the secretory granule and its involvement in intragranular acidification and 
insulin maturation 131. However, this result was in contrast to some reports from 
population-based studies that showed decreased insulinogenic index for the WFS1-H611 
allele 139, 160. One of the roles of WFS1 in the cell is restoration of ER homeostasis. In 
concordance with this, expression of both alleles protected INS-1 cells from ER stress-
mediated dysfunction. Interestingly, the R611 allele of WFS1 had a more pronounced 
protective effect. These findings suggest that the susceptibility to T2DM progression in 
the WFS1-H611 is not due to a decreased insulin output of the pancreatic β cells, but 
protection against T2DM development by the WFS1-R611 allele is borne out through the 
increased protection from ER stress and maintenance of β cell viability. 
In order to establish how the R611 allele of WFS1 was protective, a DNA 
microarray was performed focusing on genes that play a role in cell survival. The 
outcome was the identification of increased expression of netrin-1 in both allelic variants, 
which was significantly higher in the protective R611 allele. There have been a number 
of reports demonstrating the involvement of netrin-1 in pancreatic morphogenesis, 
recruitment of pancreatic progenitor cells and protection of β cells against stress 165-167. 
Thus, the increased expression of netrin-1 by islets bearing the WFS1-R611 allele may 
enable protection against apoptosis and recruitment of pancreatic progenitors as a 
mechanism to maintain β cell mass and preclude diabetes progression. 
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In this section of the thesis report, the focus was directed to those genes identified 
by the DNA microarray that were involved in cell survival; the outcome of this approach 
was the observation of alterations in expression of netrin-1 and some of the netrin 
receptors. However, the DNA microarray data included many other genes, some of which 
may also act in a similar manner to promote β cell survival. These genes may act in 
addition to or even surpass the effect of netrin-1 in WFS1-expressing cells and it would 
be interesting to re-examine the list of genes found in the DNA microarray to identify 
additional target genes. 
ER stress has been implicated in a number of diseases including 
neurodegeneration, atherosclerosis, and diabetes. With the exclusion of XBP-1, the 
majority of previous work on ER stress has focused on proteins as the final effectors 
involved in the UPR. Therefore, using a mouse model of Wolfram syndrome, the 
connection between ER stress and diabetes was further explored as a separate chapter of 
this thesis. The miRNA profile of ER stressed WFS1-deficient islets was examined to 
identify unique miRNA that sustain β cell life in chronic ER stress conditions. The 
outcome of this research goal was the detection of altered miRNA that promote β cell 
survival.  
The presence of WFS1 is fundamental to the restoration of ER homeostasis and in 
its absence unmitigated ER stress and chronic UPR activation leads to cell dysfunction 
and death. However, the loss of cells in WFS1 deficiency takes a long time to manifest as 
symptoms: diabetes occurs in the first decade of life, followed by progressive optical 
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atrophy, while ataxia appears much later in the course of the disease. This may be partly 
explained by differences in susceptibility to stress among pancreatic β cells and neurons 
or the variation in number of cells needed to be destroyed in order to exhibit 
symptomology. However, it is also possible that the cells are undergoing chronic ER 
stress and have activated specific responses to counteract that stress to maintain survival 
as long as possible.  
In chapter III, islets from the WFS1-/- mouse models of Wolfram syndrome were 
used as the paradigm to elucidate novel miRNA whose expression was induced or 
repressed by the chronic ER stressed state. In that chapter, the expression of all three 
members of the miR-29 family was found to be increased in WFS1-/- islets. Further 
examination of the miR-29b family, using miR-29b as the prototypical member, revealed 
that miR-29b decreased the expression of the ER stress markers CHOP and BiP. 
Furthermore, the expression of each of the UPR transducers, ATF6, IRE1, and PERK, 
were also diminished following treatment with miR-29b. However, there are no known 
miR-29 target sites in the 3’UTR of the UPR transducers or CHOP or BiP mRNA, 
indicating that the decreased expression of these genes is an indirect process.  
To further investigate the role of miR-29 family in maintaining β cell survival, the 
downstream ER stress-mediated apoptotic signaling was examined. Interestingly, miR-
29b expression has been reported to be increased during the maturation of neurons and 
restricts apoptosis in mature neurons by targeting the BH3-only genes for destruction 215. 
The 3’ UTR of the BH3-only PUMA and Bim-EL mRNA contain recognition sites for 
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miR-29 annealing and destruction through the RISC 215. In the current research, miR-29b 
decreased the expression of the ER stress-related pro-apoptotic factors PUMA and Bim-
EL, suggesting that miR-29 induction in WFS1-/- islets is a bona fide adaptive alteration 
generated by the β cell to restrict apoptosis under ER stressed conditions. Finally, 
treatment with miR-29b prevented the activation of caspase-3 under ER stress conditions 
in INS-1 cells. The mRNA level of the Ins2 gene was unaffected by miR-29b mimic 
administration indicating that there was not a global suppression of transcription. 
Collectively, these data propose that ER stressed β cells increase the expression of miR-
29 family members in order to counteract the heightened activation of the UPR in the cell 
in an attempt to maintain β cell survival. 
In chapter III, one miRNA family, miR-29, elucidated by the miRNA microarray 
was examined further. However, the expression of numerous other miRNA families was 
induced in WFS1-/- islets. For those miRNAs that had decreased expression, there was 
one predmininat family, the miR-467 family. Since this is a rodent-specific miRNA 
family and not found in humans, it could be acting as a contributory factor to the survival 
of β cells in the mouse in the absence of WFS1 protein. Exploration of additional miRNA 
families, either increased or decreased in the WFS1-/- mice may reveal additional targets 
for study.  
Wolfram syndrome is a rare autosomal recessive disorder characterized by the 
close association of diabetes mellitus with progressive optical atrophy. In contrast to 
T2DM and T1DM, the majority of Wolfram syndrome patients are not obese and do not 
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have insulitis. Postmortem examination reveals selective loss of β cells in the pancreatic 
islets as the contributory factor to DM in these patients 219. The gene responsible for 90% 
of Wolfram syndrome was identified by two separate groups in 1998 and termed WFS1 
119, 120. The remaining Wolfram patients have mutations in the WFS2 (CISD2) gene. 
There are over two hundred mutations in WFS1 that contribute to Wolfram syndrome, 
with the vast majority of these mutations residing in exon 8, which encodes the 
transmembrane and C-terminal domains of the protein, highlighting the role of this region 
in the function of WFS1. Even mutations in terminal seven amino acids of WFS1 are 
sufficient to cause Wolfram syndrome. The vast majority of Wolfram patients are 
compound heterozygotes 220. The absence of functional WFS1 protein leads to unresolved 
ER stress and chronic UPR activation, culminating in β cell dysfunction and death. The 
diminution of pancreatic β cell mass is slowly progressive and diabetic symptoms do not 
present during the neonatal period, but appear later in the first decade of life. This is 
possibly due to the higher regenerative capacity of younger islets 221. 
Skeptical people would argue that the contribution of mutations in WFS1 to the 
onset of diabetes mellitus in Wolfram syndrome necessitates other factors, as in a two-hit 
hypothesis. It is not unreasonable to consider that there are supplementary factors that 
affect β cell function which are involved in advancing the development of DM in 
Wolfram syndrome. However, there have been no additional genetic mutations found in 
Wolfram syndrome patients and the disease is completely penetrant in regards to DM and 
OA, the pathognomonic symptoms.  Furthermore, investigation of the deficiency of 
WFS1 and mutant forms of WFS1 have been studied exhaustively using cell culture-
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based approaches. In these systems, cells display unresolved ER stress and UPR 
activation, leading to β cell dysfunction and apoptosis. In contrast to humans with 
Wolfram syndrome, the syndrome cannot be completely recapitulated in the mouse and 
the development of overt diabetes is rare in WFS1-/- mice. However, glucose intolerance, 
a reduction in β cell mass, enhanced apoptosis, and dilated ER in the β cells are noted 130. 
To exacerbate the diabetic phenotype in WFS1 deficiency, Akiyama et al (2009) 
introduced the agouti lethal yellow mutation into the WFS1-/- mouse. The resulting 
animals had selective β cell loss and severe insulin-dependent diabetes 222.  Since there 
are a number of roles of WFS1 in the β cell, it may be plausible that different mutations 
in WFS1 affect its location-specific functions in different ways and impact the β cell 
accordingly. Thus, the combination of WFS1 mutations that are present in compound 
heterozygote patients may contribute to the demise of the β cell mass at different rates. 
The involvement of different WFS1 mutations may explain the incomplete penetrance of 
DI, sensorineural deafness, ataxia, and other Wolfram-associated findings. To determine 
the interplay of different WFS1 mutations and their contribution to DM progression 
would involve exhaustive cloning of the multitude of mutations and their co-expression 
in a combinatorial fashion. This would be possible to perform but given the fact that DM 
is completely penetrant in Wolfram syndrome in any combination of WFS1 mutations, 
the minimal return for such extensive research would not be worthwhile exploring. 
The question may arise concerning the rationale for the manifestation of distinct 
neurological and endocrine deficits in Wolfram syndrome despite the ubiquitous 
expression of the protein. The symptoms associated with Wolfram syndrome present 
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predominantly in the pancreatic β cell, optical neurons, and other neurons in the 
hypothalamus, cerebellum, and vestibulocochlear nerve. These cell types are more 
sensitive to ER stress-induced damage. In fact, due to the constant demand for insulin 
biosynthesis, β cells are dependent on a highly efficient ER and the baseline ER stress 
level is higher in these cells when compared to others 48, 95. It is tempting to state as a 
generality that all secretory cells, which include the pancreatic β cells and neurons, are 
rendered more susceptible to apoptosis in the deficiency of WFS1. This would explain 
the fact that there have been no problems identified in other non-secretory organs, such as 
the heart and muscle, in Wolfram patients. In addition, cardiac and skeletal myocytes 
have an increased rate of turnover which could mask the presentation of symptoms due to 
the absence of WFS1 protein. However, cells of the exocrine pancreas, liver, 
gastrointestinal system and immune system are also highly secretory, but there are no 
obvious symptoms associated with dysfunction of these organs in Wolfram patients. This 
highlights the specific role of WFS1 in pancreatic β cells and neurons and in its absence, 
unresolved ER stress and cell death occurs. It is widely established that, in spite of 
different embryological origins, β cells and neurons share a number of similarities, and it 
is not a huge leap to consider that the functional role of WFS1 may be consistent with 
this viewpoint 223. However, there is the possibility that there are other proteins that are 
interact with WFS1 specifically in neurons and β cells; in the absence of WFS1, these 
interactions do not occur and the cells are rendered more susceptible to ER stress-
mediated death. 
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To continue to explore the findings of the current research, one approach is to 
develop transgenic animals expressing the different allelic variants of WFS1, with the 
zinc-finger nuclease approach being a plausible unique method for rapid development of 
these animals. It would be anticipated that augmentation of WFS1 expression in these 
animals would maintain ER homeostasis in the pancreatic β cells, preventing diabetes 
progression. Challenging these animals with genetic or environmental diabetic 
precipitants and comparing with control animals may demonstrate the effect of different 
allelic variants of WFS1 in promoting β cell viability. Furthermore, the involvement of 
WFS1 alleles in insulin secretion could be more accurately assessed in these animals by 
challenging them with intraperitoneal glucose, performing hyperglycemic clamp studies, 
or isolating the islets for perfusion studies. 
This thesis demonstrates that polymorphisms in WFS1 may be involved in the 
maintenance of β cell mass through increased netrin signaling. The identification of 
chemical or biologic compounds that could enhance the function of WFS1 in the β cell 
would be a major advancement in the field of diabetes. Enhancing WFS1 would also 
target the β cell directly preventing the loss of functional β cells and circumvent the need 
for secondary diabetic medications that palliate hypoglycemia without curing the disease 
itself. Alternatively, with the identification of netrin-1 as a downstream component of 
WFS1, it may be possible to directly enhance netrin-1 signaling to maintain β cell mass.  
The second half of this thesis elucidated the role of miR-29 family members as 
adaptive compensatory mechanism to restrict ER stress-mediated apoptosis in β cells. 
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Since this was found in WFS1-deficient islets that are under chronic ER stress conditions, 
it’s possible that miR-29 family members could be released from those cells within 
exosomes and act as biomarkers for ER stressed β cells 218. The identification of 
biomarkers of stressed β cells would allow earlier treatment and limit diabetes 
progression. Alternatively, the miR-29 family could be co-opted as an adjunctive 
treatment to maintain β cell survival during human islet transplantation.  
Since there are a number of neurological symptoms in Wolfram syndrome and the 
facts that ER stress is a contributory factor to a number of neurodegenerative diseases and 
that there are a number of similarities between β cells and neurons, it may also be 
possible to apply the information derived from this thesis work to generate potential 
neuroprotective agents. Netrin-1 is involved in recruitment of β cell progenitors and 
protection against apoptosis in addition to axonal guidance during neurogenesis – would 
netrin-1 introduction lead to recruitment of neurons and neuroprotection in 
neurodegenerative diseases? The miR-29b has been shown to limit the induction of the 
UPR and restricts apoptosis in mature neurons – would exogenous miR-29 expression 
protect against ER stress-mediated neuronal cell death in amyotrophic lateral sclerosis, 
Alzheimer’s, or Parkinson’s disease? The ability to extrapolate the findings of this thesis 
work into meaningful therapeutic modalities would be challenging but would be a worthy 
attempt in order to try to prevent diabetes and neurodegenerative disease progression.  
In conclusion, the current study has provided further insight into the function of 
the WFS1 protein and identified an ER stress-regulating miRNA. The elucidation of the 
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mechanisms underlying netrin-1 induction by WFS1 remains to be established. The 
specifics of how miR-29 decreases the expression of UPR transducers also need to be 
explored. Nevertheless, these observations have expanded on the roles of WFS1 in β cells 
and demonstrated how adaptive alterations in miRNA expression can maintain cell 
survival in ER stress (Figure 4.1). These findings have opened the door for further 
research into the role of WFS1 in β cell survival and of miRNA in ER stress and diabetes. 
Ultimately, the knowledge and understanding derived from this cumulative thesis work 
may lead to the development of novel therapies for ER stress-related diseases, which 
includes diabetes. 
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Figure 4.1: Summative conclusions from current thesis. Chapter II revealed increased 
netrin-1 signaling by WFS1, especially the R611 allele. Netrin-1 is β cell-protective and 
recruits pancreatic progenitors. In chapter III, WFS1-/- islets showed increase expression 
of miR-29 family members. miR-29 members regulate the expression of UPR transducers 
and UPR-related apoptotic factors. 
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